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INTRODUCTION 
Immunological research has made enormous progress during the las t ten 
years, t h a n k s to the development of new techniques, such as the 
cloning of Τ cells, the recombinant DNA technique, and the production 
of hybridomas. Τ cell clones are used to study cellular interact ions, 
production of lymphokines, and the recognition of antigen. The 
application of the recombinant DNA technique has given information 
about gene s t ructures , including MHC genes, oncogenes and 
oncogene-related gene products, and the recombination during the 
rearrangements of genes in В and Τ cell ontogeny. The hybridoma 
technique, which was introduced in 1975 by Köhler and Milstein (1), 
implies the immortalization of ant ibody-producing cells (B cells). 
Immortalization of the cells is established by fusion of spleen cells, 
harves ted after appropriate immunization, with continuously growing 
mouse myeloma cells. These hybrid cells can be cultured and cloned in 
vitro, and have the combined propert ies of the parental cells; the 
capacity of the spleen В cell to produce antibodies with a dis t inct 
specificity and the continuous growth potent ia l of the myeloma cell. 
In this way reagents can be obtained in large quant i t ies t h a t are 
highly specific for the antigen which was used for immunization. 
Originally, the technique was developed to invest igate the nature and 
genetic origin of antibody diversity, using monoclonal antibodies 
(MAb) directed against sheep red blood cells. The potential value of 
this technique as an immunological tool in diagnostic, therapeut ic, 
and analyt ical research was soon realized. Up till now, a large number 
of MAb have been described against viral, bacterial, parasi t ic, and 
tumour ant igens, against haptens, hormones, and cell surface ant igens . 
Τ cell differentiation antigens. 
MAb directed against cell surface ant igens have been used as an 
instrument to study the morphology and morphogenesis of t i ssues. 
Especially the study of the differentiation of lymphoid cells has been 
developed t h a n k s to the monoclonal antibody technique. Lymphoid colls 
are derived from the bone marrow, where stem cells reside. The progeny 
of p lur ipotent or committed slem cells migrate from the bone marrow 
into the peripheral lymphoid organs to differentiate into mature Τ or 
В lymphocytes. The Τ cell precursor cells migrate as prothymocytes 
into the thymus, where further maturat ion occurs. In 1980 Reinherz et 
al. (2) developed a hypothetical scheme of the origin of Τ cells as 
analyzed with MAb. This scheme has been supplemented later by several 
10 
lymphoid 
stem cell 
TdT 
HLA-DR 
Figure 1. Τ cell differentiation. 
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investigators (fig.l). Since the nomenclature of the Τ cell differen­
tiation antigens varied per research group, a universal nomenclature 
was proposed during the First International Workshop on Human 
Leukocyte Differentiation Antigens to avoid difficulties in communi­
cation. At present seven Clusters of Differentiation (CD) on Τ cells 
or Τ cell subsets have been defined. 
The lymphoid stem cell is characterized by the presence of HLA-DR and 
by the nuclear enzyme terminal transferase (TdT). Although its 
function is not clear, it has been suggested that TdT is involved in 
increasing diversity in the D (diversity) J (joining) segments of 
receptor genes (3). The prothymocyte expresses additionally CD7 (a 40 
kD glycoprotein) (4), and CD2. The CD2 molecule, also named T i l , was 
originally described as the sheep red blood cell receptor, and is a 
50-58 kD glycoprotein (5). It binds to the cell surface antigen LFA-3, 
and can mediate adhesion of lymphoid cells via interaction with LFA-3 
(6). The immature common thymocyte acquires subsequently the CD5 (67 
kD) (7), CD1 (40 kD) (8). CD4 (55 kD) (2) and CD8 (a heterodimer of 76 
kD) (2) antigens. Upon further maturation GDI and either CD4 or CD8 
are lost from the cell surface (2). The mature thymocytes are 
immunocompetent cells and express the CD3 antigen. The CD3 antigen 
consists of a group of noncovalently associated proteins: -y (25 kD), 
-8 (20 kD), - € ( 2 0 kD), and - ζ (16 kD) chain (9, 10). This antigen 
complex is closely associated with the Τ cell receptor (TCR), a 
disulphide-linked variable heterodimer of 90 kD (a and β chain), or, 
on a small minority of the peripheral Τ cells (less than 5%), with the 
Τ cell receptor y (TCR^ polypeptide (11). The CD3 positive cells 
enter the peripheral blood as antigen-specific Τ lymphocytes, being 
either CD4 or CD8 positive. The CD4 positive cells (approximately 65% 
of the peripheral Τ cells) are generally MHC-class II restricted in 
the recognition of antigen, and are mainly involved in helper and 
inducer functions. The CD8 positive cells (approximately 35% of the 
peripheral Τ cells) include the suppressor/cytotoxic Τ cells, and are 
mainly MHC-class I restricted in the recognition of antigen. The CD4 
and CD8 markers do not provide a strict separation of these different 
functional properties, since CD4 positive cytotoxic Τ cell clones have 
been described (12, 13). Similarly, CD4 positive MHC-class I specific, 
and CD8 positive MHC-class II specific cells have been found (12, 14, 
15). The production of interleukin-2 (IL2), the essential Τ cell 
growth factor necessary for growth of Τ cells, natural killer (NK) 
cells and of В cells (16), is a property of CD4 positive cells as well 
as CD8 positive cells (17). 
12 
Functional aspects of Τ cell differentiation antigens. 
The use of MAb directed against the different ant igens in functional 
assays, has provided insight into the function of the Τ cell ant igens . 
For example, the CD4, CD8, CD2, and t h e CD3 ant igens are each in the i r 
own way involved in the recognition of antigen. The recognition of 
antigen by CD4 posit ive cells or CD8 posit ive cells can be blocked by 
MAb anti-CD4 or anti-CD8 respectively, as revealed by inhibit ion 
studies of the antigen-specif ic cytotoxicity. Anti-CD4 MAb block the 
MHC-class II res t r ic ted lysis by CD4-positive cytotoxic Τ lymphocytes 
(CTL), whereas anti-CD8 MAb inhibit the MHC-class I res t r ic ted lysis 
by CDS-posltive CTL, both at the adhesion s tep in the cytolytic 
process. Therefore, the usual ligands for CD4 and CD8 are thought to 
be MHC-class II and class I molecules respectively. The puta t ive 
function of these molecules is to stabil ize the conjugate formation 
between the target cell and the effector cell. Recently, however, i t 
has been described, t h a t anti-CD4 MAb could also block t h e 
proliferation response of CD4 posit ive lymphocytes induced by 
mitogenic stimuli. This inhibition occurs a t a la te s tage in the Τ 
cell act ivat ion process, since t h e act ivat ion pulse, as measured by 
the rise of cytoplasmic Ca2*, is not affected. Therefore, the CD4 
molecule is thought to be involved in a p o s t - a c t i v a t i o n event of CD4-
positive lymphocytes (18). A similar role has been suggested for the 
CD8 molecule, since anti-CD8 MAb could inhibit the lytic act iv i ty of 
CTL after the binding of CTL to the ta rge t cell. It h a s been sugges­
ted, t h a t the CD8 molecule plays a role in negat ive signalling to the 
Τ cell, prevent ing Τ cell triggering by nonspecific interact ion (19). 
The CD2 antigen has also a function in the interact ion of the Τ cells 
with antigen, since some, but not all, MAb directed against CD2 are 
able to block antigen dependent helper Τ cell proliferation and to 
inhibit the cytolytic process a t the s tep of the conjugate formation 
(20). It has been proposed, t h a t d i s t inct epitopes on CD2 are involved 
in different processes, since MAb directed against different epitopes 
on CD2 can have different effects in functional assays (21). The CD2 
antigen appears to be involved in Τ cell act ivat ion, since a combina­
tion of two MAb, directed against different epitopes on CD2 termed 
T i b and Т П з , are able to induce Τ cell proliferation and IL2 
release (22). Triggering of the CD2 antigen by anti-CD2 MAb leads to 
an increase of intracel lu lar free Ca2* (23). Moreover, it has been 
described t h a t the combination of a n t i - T l l a and a n t i - T i l s MAb induce 
an antigen nonspecific cytolytic act iv i ty in cytolytic Τ cells (24). 
Anti-CD3 MAb can have apparent ly opposite effects on Τ cells. On the 
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one hand, they block Τ cell act iv i t ies , such as the proliferation of Τ 
cells to soluble antigen (25), or the antigen specific cytotoxicity 
(26). On the other hand anti-CD3 MAb induce act ivat ion of Τ cells, 
e.g. an increase of intracel lular free Ca2*, mitogenesis, expression 
of IL2-receptors, secretion of gamma-interferon by Τ cells (23, 27, 
28, 29), and induce a nonspecific lytic act iv i ty by cytotoxic Τ cells 
(this thesis) . Thus, anti-CD3 MAb ei ther block antigen specific 
responses, or mimic the act ivat ion process, depending on the assay 
used. This react iv i ty pat tern can be explained by the finding, t h a t 
the CD3 antigen is associated with the TCR. The TCR serves for the 
specific recognition of antigen, whereas subsequently the CD3 complex 
t ransduces the signal through the cell membrane. 
Other Τ cell differentiation antigens are the CD7 molecule and the CD5 
molecule. Anti-CD7 MAb have no effects on Τ lymphocytes in in v i tro 
assays, but have immunosuppressive act iv i t ies in a skin allograft 
model, suggesting t h a t this antigen is important for Τ cell function 
(this thesis) . Anti-CD5 MAb can bypass the need for accessory cells in 
Τ cell act ivat ion, providing the necessary addit ional signal (30). 
Application of MAb directed against Τ cell differentiation 
antigens. 
MAb directed against lymphocyte surface ant igens have already been 
used in the diagnosis and t reatment of many diseases. For a number of 
diseases, an association has been establ ished between increased or 
decreased number of suppressor cells, as judged by CD4/CD8 ratios and 
disease act iv i ty (31). Also for the diagnosis of lymphomas and l e u k e -
mias, antibodies directed against lymphocyte differentiation ant igens 
have proved to be highly useful. One of the antibodies discussed in 
this thes is WTl (anti-CD7) is very useful in the diagnosis of T-ALL 
(thymic acute lymphoblastic leukemia) (32) and proved to be a good c a n ­
didate for immunotherapy, when conjugated to the toxin Ricin A (33). 
Besides their diagnostic value, in vivo therapy with MAb is a rapidly 
developing field and one of the applications is the induction of 
immunosuppression. Already 20 years ago polyclonal antibodies directed 
against lymphocytes (ALG, ant i- lymphocyte globulin) have been used as 
an immunosuppressive drug in clinical t r a n s p l a n t a t i o n (34). The first 
randomized clinical t r ia l where more specific antiserum, i.e. 
ant i- thymocyte globulin (ATG), was used to reverse renal allograft 
rejection, was undertaken in 1979. ATG appeared to be very effective 
in improving graft survival (35). 
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MAb for immunosuppressive therapy. 
To further increase the specificity of antibody t r e a t m e n t by removing 
defined lymphoid populat ions, and to reduce the amount of foreign 
protein administered to the pat ients , MAb directed against Τ cells 
have been tes ted. An obvious choice is anti-CD3 MAb, since th i s 
antibody is able to block the proliferative response to ant igen in 
vitro and the cytotoxic effector function of the Τ cells. OKT3 
(anti-CD3) MAb has been successfully used to t r e a t acute renal 
allograft rejection (36, 37). Another anti-CD3 MAb WT32 proved also to 
be suitable for rejection t reatment (38). Many other monoclonals have 
been applied for th i s purpose, but they all proved to be less powerful 
than anti-CD3. WT1 (anti-CD7), tes ted in the Rhesus monkey (this 
thesis) and OKT4 (anti-CD4), tes ted in the Cynomolgus monkey (39) were 
shown to improve the survival of skin and renal allografts 
respectively. 
The mechanism by which anti-CD3 MAb exerts i t s function as an immu­
nosuppressive drug is not yet clear and needs further invest igat ion. 
Probably, Τ cells are eliminated via the mononuclear phagocytic system 
following opsonization. Binding of anti-CD3 MAb also causes modulation 
and internal izat ion of the CD3-antigen. In th i s way the Τ cells loose 
the CD3-antigen and are rendered nonreact ive to antigen. 
Fc -receptors and immunosuppressive therapy. 
The requirement for Fc-mediated processes in the induction of immuno­
suppression h a s been demonstrated by the finding t h a t F(ab')2 
fragments of polyclonal ATG were ineffective (40). In many a p p l i ­
cations of MAb in vivo, Fc-mediated mechanisms are triggered which can 
be beneficial, e.g. elimination of target cells, ac t iva t ion of 
effector cells, elimination of soluble antigen. Therefore, it is of 
importance to inves t igate the interact ion of murine antibodies with 
the receptors for IgG on human cells. 
The interact ion of the Fc-receptor with IgG is more complicated and 
heterogeneous t h a n was thought h i ther to . Fc-receptors on macrophages 
are involved in endocytosis of immune complexes (41), antibody 
dependent cel l-mediated cytotoxicity (ADCC) (42), st imulat ion of the 
release of inflammatory mediators (43), and superoxide production 
(44). Analysis of the murine Fc-receptor revealed t h a t individual 
cells may have more than one type of Fc-receptor; mouse macrophages 
possess three types of Fc-receptois for murine IgG; a trypsin 
sensi t ive receptor for monomeric IgG2a (FcRI) (45); a t rypsin 
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resistent receptor, binding preferentially aggregated IgGl and IgG2b 
antibodies (FcRII) (46); and a receptor for aggregated IgG3 (FcRIII) 
(47). Heterogeneity in specificity of Fc-receptors is found for 
different cell types: mouse В cells carry an Fc-receptor, binding 
murine IgGl, IgGSa, and IgG2b, but not IgG3, which thus differs in 
its specificity from the Fc-receptors on macrophages (48). 
In man, three types of Fc-receptors for human IgG are known; 1) a 72 
kD (FcRI), 2) a 40 kD Fc-receptor (FcRII), and 3) an Fc-receptor with 
low affinity (50-70 kD) (FcRio) (49. 50, 51). The human FcRI (HFcRI) 
is present on monocytes, whereas the HFcRII is also present on 
macrophages, platelets, granulocytes and В cells. The HFcRio is 
expressed on neutrophils, eosinophils, macrophages, natural killer 
cells, killer cells, large granular lymphocytes, and Tv cells (52). 
Some homology with murine Fc-receptors was supposed, since HFcRI binds 
selectively murine IgG2a, and HFcRII interacts with murine IgGl (49). 
Sofar, however, the homologue of the HFcRio has not been found on 
mouse cells. 
Aim of this study 
The aim of this study was to investigate some biological activities of 
the pan-T cell differentiation antigens CD3 and CD7. The functional 
studies were initiated in view of possible future application of MAb 
for clinical immunosuppression. The CD7 antigen was chosen, because 
its expression strongly increases upon activation of Τ cells. In 
Chapter II a MAb (WT1) is characterized and tested for its immuno­
suppressive actitvity in a Rhesus monkey model. Its value for 
diagnosis of T-ALL and its therapeutic use are discussed. 
In Chapter III a novel effect of MAb directed against the CD3/TCR 
complex is described: the induction of nonspecific cytotoxicity, i.e. 
antigen specific cytotoxic T-cell lines as well as cytotoxic T-cell 
clones (Chapter IV) can be triggered by anti-CD3 MAb to mediate 
antigen-nonspecific cytotoxic activity. This process is Fc-dependent; 
crosslinking occurs between the Fc-part of the anti-CD3 MAb and the 
FcR on the target membrane, resulting In an effective triggering of 
the cytotoxic Τ cell. Not only FcR-positive cells, but also CD3 
positive cells are prone to this induced lysis (Chapter V). 
Knowledge regarding human FcR for murine antibodies is of great 
importance, since murine MAb will be widely used in vivo for 
therapeutical application, e.g. antitumor therapy and anti-rejection 
therapy. Because the antibodies exert their function in many processes 
via FcR, the study of the interaction of murine antibodies with human 
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FcR is of great importance. The anti-CD3 induced cytotoxicity appeared 
to be a useful tool to provide information on the interaction of FcR 
on human cells with murine IgG. In Chapter VI a study on the 
characteristics and functional properties of FcR for murine IgG on 
human monocytes and В cells is described. 
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SUMMARY 
WT 1, an IgG2a subclass monoclonal antibody, recognizes a human Τ lineage specific 
antigen (mol wt 40,000) This antigen is strongly expressed on thymic Τ blasts, and on 
peripheral Τ cells activated by phytohaemagglutinin, whereas cortical thymocytes and 
peripheral Τ cells are moderately positive for WT 1 In contrast, В lymphocytes, myeloid 
and erythroid cells, including the progenitor cells of these lineages, and terminal 
deoxynucleotidyl transferase positive cells in the bone marrow, are all WT 1 negative 
Binding of WT I to 1 cells is blocked by a previously described antibody (ЗА I ) suggesting 
that both antibodies bind to the same antigen present on human Τ cells WT 1, however, is 
also reactive with Γ lymphocytes from rhesus monkeys whereas ЗА 1 is not Therefore, the 
biological effects of WT 1 could be studied in a monkey model In a skin allograft model, 
WT 1 was immunosuppressive and induced a marked prolongation of graft survival 
Keywords monoclonal antibodies Τ cells leukaemia immunosuppression 
INTRODUCTION 
Monoclonal antibodies (MoAbs) have now been produced against several Τ cell differentiation 
antigens Among these are antibodies reactive with essentially all rhature Τ cells but with only a 
fraction of the thymocytes (e g OKTl and OKT3, reviewed by Reinherz & Schlossman, 1980) 
Antibody OKTl 1, reactive with the receptor for sheep erythrocytes (Verbi et al, 1982), binds to all 
Τ cells as well as to the great majority of thymocytes, but it does not react with E rosette negative 
thymocytes This E rosette negative subpopulation of thymocytes is an interesting subset with 
respect to thymocyte differentiation and malignancy Cells from 10-15% of T-ALL patients (T cell 
origin of the cells based on reactivity with xenogeneic anti-T antiserum) do not form E rosettes 
(Janossy el al, 1980b) and are frequently unreactivewith the other OKT reagents (Greaves, 1981) 
Therefore, a further pan Τ reagent is needed which reacts strongly against these E rosette negative Τ 
lymphoid cells WT 1 fulfills this purpose because it reacts with all thymocytes, including large blasts 
of putative early stages of differentiation, and also binds to the vast majority of peripheral Τ cells A 
similar tissue distribution has been described for the antigen recognized by antibody 3A1 (Haynes, 
Eisenbarth & Fauci, 1979, Haynes, 1981) We found that WT 1 and3Al bind to the same antigen 
Correspondence Dr Wil J M Tax Deparlmenlof Medicine. Division of Nephrology. Si Radboudzieken­
huis, Geert Grooteplein Ζ 8 6525 GA Nijmegen The Netherlands 
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since the binding of WT 1 is blocked by 3A1 In contrast to WT 1, however, 3A1 also binds to 
monocytes (Haynes, 1981) and acute myeloid leukaemia cells (Van Der Reijden et al, 1982) This 
reactivity appears to be not antigen specific but mediated through the Fc portion of the antibody 
(Haynes, 1981) There is another important difference between ЗА 1 andWT 1 WT 1 is reactive with 
Τ lymphocytes from rhesus monkeys, whereas ЗА 1 is not (Haynes el al, 1982) Therefore, we were 
able to test the biological effects of antibody WT 1 in ι no in monkeys The antibody proved to be 
immunosuppressive in a rhesus skin allograft model, and showed no toxic side effects at all in these 
animals Detailed studies were performed to ascertain that the reactivity of this antibody is 
restricted to Τ lineage cells in thymus and other peripheral lymphoid organs, and that the antibody 
does not react with bone marrow precursor cells 
MATERIALS AND METHODS 
Preparation of WT I Thymocytes (107) from an infant thymus which was removed during 
cardiac surgery, were injected intrapentoneally in Freund's complete adjuvant mio a female 
BALB/c mouse Three weeks later, 107 thymocytes of the same frozen sample were injected 
intravenously on 4 consecutive days before cell fusion (Tax et al, 1982) The spleen cells were fused 
with Sp2 0 in the presence of PEG 1500 as previously described (bazekas de St Groth & 
Scheidegger, 1980) The antibody was purified from ascites by ammonium sulphate precipitation 
and protein A-Sepharose affinity chromatography The subclass of antibody WT 1 was determined 
by Immunoelectrophoresis in agarose using subclass specific anubodies (Meloy, Springfield, 
Virginia, USA) and was confirmed by indirect immunofluorescence using subclass specific 
fluorescein conjugated antibodies (Nordic, Tilburg, The Netherlands) The light chain type of WT 1 
was determined by Immunoelectrophoresis using rabbit anti-lambda or -kappa chain (Litton 
Bionetics, Kensington, Maryland USA) Isoelectric focusing of purified WT 1 was performed on 
prefabricated gels on a pH gradient of 5 5-8 5 (LK.B, Bromma, Sweden) and proteins were 
visualized by Coomassie blue staining 
Additonal reagents The MoAbs used were WT 32, an OK.T3 like antibody (Tax et al, 1983c), 
UCHT 1 (another OK.T3 like antibody, a gift from Dr Ρ Beverley, Beverley & Callard, 1981), 
NA1/34 (which reacts with HTA-1 cortical thymocyte antigen, a gift from Dr A McMichael, 
McMichael et al, 1979), OKTll (an antibody to the sheep erythrocyte receptor, Ortho 
Pharmaceutical Co , Rantan, New Jersey, USA , Verbi et al, 1982), WT 2 (which reacts with bone 
marrow precursor cells. Tax et al, 1982), and 3 A1, generously provided by Dr В Haynes (Haynes et 
ai. 1979, Haynes, 1981) 
Conventional antisera were goat anti-human IgM. directly labelled with fluorescein isothio-
cyanate (FITC), chicken anti-HLA-DR and rabbit anti-terminal transferase (anti-TdT, Janossy et 
al, 1980a) The second layer antibodies made in goat and sheep against mouse, chicken and rabbit 
Ig were labelled with FITC (green) or tetramethyl rhodaminc isothiocyanate (TRITC, red) and used 
in appropriate combinations as shown below 
¡mmunoprecipitation MOLT-3 cells were surface lodinatcd, and lysed with 0 5%NP-40 Lysates 
were pre-cleared and then incubated with antibody Formalin fixed Staph\lococcus ашеич bacteria 
were used for the precipitation Molecular weight of the antigen recognized by WT 1 and 
determined by SDS-polyacrylamide gel electrophoresis under reducing conditions (Laemmli, 
1970) 
Cells and cell culture Cell lines were cultured in RPMI 1640 medium (Dutch modification, 
containing both HEPES and sodium bicarbonate) supplemented with 7 5-15% heatinactivated fetal 
calf serum, 2 т м glutamine, 1 т м sodium pyruvate and gentamycm (50 /ig/ml) The characteristics 
of the lines have been described previously (Minowada et al, 1978) Mononuclear cells from blood 
and bone marrow were isolated on Ficoll-Isopaque (Pharmacia, Uppsala, Sweden) Stimulation 
with phylohaemagglutinin (PHA, 50 μ% ml) was performed in the same medium as above except 
that 20% human AB serum was substituted for calf serum Granulocytes and thrombocytes were 
purified as described (Tax et al ,1982), and monocytes were obtained by the elutnation technique 
(De Mulder et al. 1981) 
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Immunofluorescence and immunoperoxidase Cells were incubated with MoAb (culture superna­
tant used at 1/10, or ascites at 10~3or IO - 4 final dilution), orwith anti-sera (diluted 1/20- l/40)inthe 
presence of azide (0 1%), washed and stained with the relevant fluorochrome conjugated second 
layers in suspension Results of double fluorochrome staining were evaluated on a ZeibS microscope 
equipped with an epifluorescence attachment and selective filters for FITC and TRITC 
Quantitative analysis of antibody binding was performed on an EPICS V cell sorter/analyser 
(Coulter, Hialeah, Honda, USA) using an argon laser (power 400 mW at 488 nm) with 
fluorescence channel photomultipher (tube voltage 700 V) Staining for nuclear TdT was 
performed on cytocentrifuge spreads prepared from suspensions of cells which had been 
pre-labelled for membrane markers (Janossy et al, 1980a) Immunoperoxidase staining was 
performed in sections of frozen biopsies obtained from thymus and tonsil tissues (Verbi etat, 1982) 
The incubation time for antibody labelling was 45 mm to 1 h at room temperature for both first and 
goat anti-mouse Ig peroxidase second layers After peroxidase labelling, the sections were 
counterstamed with Haemalum 
Enzyme linked immunoassay (ELISA) Flat bottomed microtitrc plates were coated with 
poly-L-lysme (0 1 mg/ml, 200/jl/well)for30min Each well received 100 μΐ cell suspension(l-2x 106 
cells/ml, or 107 thrombocytes/ml) After centrifugation (5 mm 40jf), cells were fixed with 
glutaraldehyde (0 025%, 15 mm) and washed with PBS ELISA tests were performed with 50 μ\ 
samples of diluted culture supernatant or ascites fluid After incubation for 1 h and extensive 
washings with phosphate-buffered saline (PBS), pH 7, 100 μ\ of peroxidase-labelled rabbit 
anti-mouse IgG (diluted in PBS containing 1% bovine serum albumin) as added After further 
incubation (1 h), plates were washed and 100 μΐ of substrate solution (0 08% 5-aminosalicylic 
acid + 0 02% H2O2 in 50 т м phosphate buffer, pH 6 0) was added After 30 mm, extinction at 450 
nm was measured using Multiscan (Flow, Irvine, Scotland) plate reader 
Binding of '^¡-labelled antibody Purified WT 1 was labelled with l25I using the chloramine-T 
method (Hunter, 1973) Target cells were incubated with radiolabelled antibody for 30 mm at 20 С 
in the presence of azide (0 1 %) in a final volume of 60 μΐ, and washed extensively Radioactivity was 
counted in LKB gamma counter 
In vitro grow th of bone marron cells Bone marrow cells were treated with antibody and rabbit 
complement and tested for CFU-GM, as described (Tax et al, 1982) The BFU-E test was adapted 
from Iscove, Sieber & Wmterholter (1974) Orange-to-red colony bursts of at least three 
subclusters, or one single cluster of more than 300 cells were scored as BFU-E on day 14 of culture 
Skin grafting Male rhesus monkeys were grafted with allogeneic skin as described elsewhere 
(Van Vreeswijk & Balner, 1980) Starting from 2 days prior to transplantation, treated animals 
received during 10 days daily injections of purified WT 1 at a dose of 1 5 mg/kg body weight 
RESULTS 
Characteristics of WT 1 
WT is an IgG2a antibody with lambda light chain It activates rabbit complement and binds to 
protein A Isoelectric focusing ofpunfied antibody reveals a restricted pattern of bands near pH 6 5 
(data not shown) The antigen precipitated by WT 1 has an apparent molecular weight of 
approximately 40,000 The diffuseness of the single peptide band suggests a high carbohydrate 
content (data not shown) 
Tissue section analysis 
Immunoperoxidase studies revealed that WT 1 labelled both cortical and medullary lymphocytes in 
the thymus, but failed to react with non-lymphoid cells such as cortical epithelium and dendritic 
cells in the medulla (Fig la) In tonsil (Fig 1 b), the staining was restricted to the paracortical Τ cell 
areas and to 10-15% of cells in the germinal centres OK.T11 showed the same reactivity, these 
positive cells are likely to be Τ cells (Verbi et al, 1982) The Β blast cells in the germinal centres and В 
lymphocytes in the lymphocytic corona were apparently negative, and other non-T cells (e g 
follicular dendritic cells, endothelium, etc ) also failed to stain 
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Table 1. Double immunofluorescence using WT 1 and other reagents in cell suspensions 
Cell type 
Blood mononuclear cells 
Thymocytes 
Tonsil cells 
Bone marrow cells 
Combination 
TRITC/FITC 
WT 1 'UCHT 1 
WT 1/OKTll 
WT 1/anti-IgM 
WT 1/anti-HLA-DR 
WT 1 'UCHT 1 
WT Ι,ΟΚΤΙΙ 
WT l/anti-TdTi) 
WT IUCHT 1 
WT 1 anti IgM 
WT 1 anti-HLA-DR 
WT 1'UCHTl 
WT 1 OKT11 
WT 1 anti-HLA-DR 
WT 1 anti-IgM 
WT 1 'anti-TdT 
Percentage of cells 
+ / + 
76Í 
79 
<1 
<1 
20 
95 
74 
65Í 
2 
2 
10 
11 
0 2' 
0 6«-
0 
positivc't 
+ i-
4 
<1 
77 
85 
72 
<1 
21 
4 
66 
62 
0 
<1 
10 
12 
10 
- / + 
10 
λ 
6 
6 
3 
<1 
<1 
8 
29 
35 
0 
<1 
15 
5 
4 
10 
18 
17 
9 
5 
5 
5 
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Τ 
3 
90 
88 
75 
83 
86 
•Results of one representative experiment are shown Similar results were 
seen in two other tests When two MoAbs were used simultaneously, we employed 
subclass specific reagents (goat anti-mouse IgG2 TRITC for WT 1 and anti-IgGi 
UTC for the other antibody) as described previously (Tidman et al, 1981) 
Anlisera to IgM, HLA-DR and TdT were heterologous reagents (Janossy et ai, 
1980a) 
t 4-/+ and — /— refer to cells which are reactive or unreactive with either 
antibody, + / - and - ; + refer to cells which react only with the first or second 
reagent, respectively 
Í Variable staining intensity 
() See Fig 2 for further detail 
r
 These are minute populations which represent 2-5% of HLA-DR + cells of 
myeloblast morphology and 10-12% oflgM В lymphocytes in the bone marrow 
Analyst* of cell suspensions 
Double label immunofluorescence studies were performed on cell suspensions from different 
lymphoid organs In tonsil, virtually no IgM positive В lymphocytes were WT 1 positive (only 2% 
double labelled cells in Table 1 ), confirming the tissue section analysis WT 1 positivity was confined 
to the U C H T 1 positive Τ cell population, although some of these cells stained very weakly with WT 
1, There was a slight overlap between WT 1 and HLA-DR staining I his apparently corresponded 
to the weakly HLA-DR positive, U C H T 1 positive Τ cells (probably activated Γ cells), whereas the 
strongly HLA-DR positive tonsil cells (B lymphocytes) were all WT I negative 
The analysis of peripheral blood confirmed the studies on tonsil, and also showed that 
monocytes were WT 1 negative A few residual polymorphs present in the mononuclear cell fraction 
were also unreactive, a finding which was confirmed in isolated granulocyte populations from 
Fig. I. Analysis of sections of human thymus (a) and lymph node (tonsil, b) with WT1 using immunoperoxidase 
Thymocytes in both the cortical (C) and medullary (M) areas positively stain with WT 1 In the tonsil, staining is 
restricted to cells of the paracortical Τ cell area (T) and about 10o
o
 of lymphocytes in the germinal centre (GC) 
The staining intensity of these Τ cells is very variable (which is better demonstrated in sections labelled for WT 1 
in immunofluorescence tests, not shown) χ 200 
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WT-1 TdT Phase 
Fig. 2. Double labelling of thymocyte suspension with WT 1 (membrane staining with TRITC in A) and terminal 
transferase (TdT. nuclear staining with FITC in B) Large strongly TdT+ thymic blasts are particularly 
intensively labelled (arrow) while small cortical thymocytes are moderately strongly positive for WT 1 ( χ 650). 
blood. Platelets were also WT 1 negative. The non-reactivity of WT 1 with thrombocytes and 
monocytes was confirmed by ELISA tests on purified cells. 
In cell suspensions from infant thymus. 95% of the cells were WT1 positive, with a variable 
staining intensity. Flow cytometry showed that the largest Τ lymphocytes (1-5% of the total 
population) gave strong staining (data not shown). Double staining with nuclear TdT on cytospin 
preparations indeed confirmed that the large WT 1 positive blast cells were also strongly TdT 
positive (putative prothymocytes? Fig. 2). Cortical thymocytes (TdT positive cells in Fig. 2) were 
moderately positive with WT 1. Medullary thymocytes showed a variable staining and on some of 
these cells the staining was hardly detectable. Approximately 3% of thymocytes were UCHT 1 
positive (peripheral type or medullary Τ cells) but WT 1 negative (Table 1) 
Double staining revealed that TdT positive cells in the normal bone marrow were invariably WT 
1 negative (Table 1 ). About 10% of bone marrow cells were WT 1 positive but these were mature Τ 
cells as evidenced by double labelling with UCHT 1 or OKTU (Table 1). More than 80% of 
HLA-DR positive cells in bone marrow (including myeloid precursors and В lymphocytes) were 
WT 1 negative. Nevertheless, a small proportion of cells with myeloblast features (2-5% of large 
HLA-DR positive cells; 0 04-0 1% of all bone marrow cells) were WT 1 positive, albeit weakly. 
Similarly. 10-12% of IgM positive bone marrow cells (0 5-0 7°
 0 of all bone marrow cells) were also 
moderately WT 1 positive. This could have been due to the binding of goat Ig to Fc receptors. In our 
hands, F(ab')2 reagents in general gave weaker staining than whole Ig second layers. Therefore, a 
very weak but genuine antigen specific reaction to a small proportion of myeloblasts and В cells 
could not be totally excluded. 
When human cell lines were tested for their reactivity with WT 1, only T-ALL lines were found 
to be positive (Table 2). WT 1 was strongly positive on Τ blasts of all these lines (except HPB-ALL), 
and staining was more uniform than with OKT11. Importantly, WT I strongly reacted with all cells 
of the CCRF-CEM line, which is an E rosette negative, OKTl 1 negative cell type. The intensity of 
WT 1 staining was even more impressive when compared to the weak and variable staining seen 
with N A 1 /34 antibody, which detects the ΗΤΑ-1 (OKT6 like) cortical thymocyte antigen (Table 2). 
Interestingly, the common ALL cell lines (KM-3, Reh), the pre-B cell line NALM-6 and В cell lines 
(such as Raji and Bristol-J) as well as the only myeloid line tested (HL 60) were all negative with WT 
1, confirming the Τ lineage specificity of this antibody. 
Antibodies WT 1 and3Al 
The antigenic specificity of WT 1 appears to be similar to that described for antibody 3A1 (Haynes 
et al., 1979; Haynes, 1981), although only limited information is available about the reactivity of the 
latter antibody with the various cell types of the bone marrow. Furthermore, the antigen 
precipitated by ЗА 1 also has a molecular weight of 40,000. Pre-incubation of Τ cell line Jurkat with 
antibody ЗА 1 blocked the binding of radiolabelled WT 1 as effectively as unlabelled WT 1. Similar 
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Table 2. Comparative reactivity of WT 1 and other MoAbs with human lymphoid cell lines and the H L 60 
promyelocyte line 
Cell line 
Ί-ALL lines 
Molt3 
Molt-4 
HPB-ALL 
HPB-MLT 
CCRF-CEM 
T-ALL 
T-CLL 
JM-1 
WT1 
>99 
>99 
50 
>99 
>99 
>99 
>99 
>99 
C-ALL and pre-В Ітеч 
KM-3 
Reh 
NALM-6 
B-lmes 
Raji 
Daudi 
Promyelocytic 
HL 60 
<1 
<1 
3 
<1 
12(±) 
line 
<1 
OKT1I 
>99 
72 
>99 
65 
<1 
>99 
>99 
>99 
<1 
<1 
<1 
<1 
9(±) 
<1 
NA/36· 
(OKT6 like) 
65 
64 
91 
56 
32 
>99 
>99 
63 
<1 
<1 
< l 
<1 
< l 
<1 
* Reactive with HTA-1 cortical thymocyte 
antigen (McMichael eí al, 1979) 
results were obtained with another Τ cell line, HSB-2, and with PHA stimulated Τ cells (data not 
shown) Therefore, both WT 1 and 3A1 appear to react with the same antigen However, as will be 
shown below, the epitopes recognized by these antibodies are different 
Reactivity of WT 1 with rhesus lymphocytes 
In rhesus monkeys 78+ 15% of peripheral mononuclear cells (mean + standard deviation for six 
animals) were OKT11 positive, and 61%+ 10% of these Τ cells were reactive with WT 1 We could 
confirm that antibody 3A1 is not reactive with rhesus Τ cells (Haynes et al, 1982), and thus reacts 
with a different epitope Previous experiments in two rhesus monkeys showed that administration of 
WT 1 resulted in a prolonged survival of skin allografts, indicating that WT 1 has immunosuppres­
sive activity (Jonker et al, 1983) We performed skin grafting in an additional rhesus monkey 
treated with WT 1, and found that allograft survival was also prolonged in this animal (graft 
survival 18 days) No toxic side-effects were observed after injection of the antibody 
Non-reactwity of bone marrow precursor cells 
In addition to the immunofluorescence studies described in Analysis of cell suspensions, we also 
performed functional assays of bone marrow cells to ascertain that the elimination of cells by WT 1 
does not interfere with the outgrowth of progenitor cells Bone marrow cells were treated with WT 1 
and complement (rabbit serum) and assessed for the growth of granulocyte/monocyte colony 
forming cells (CFU-GM) and erythroid burst forming cells (BFU-E) The growth of these precursor 
cells was not inhibited (Table 3) WT 2 (a MoAb directed against bone marrow precursor cells. Tax 
et al, 1982) in combination with complement abolished both CFU-GM and BFU-E completely As 
expected, WT 32 (OKT3 like. Tax et al, 1983c) plus complement had no adverse effect (Table 3) 
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Table 3. Functional analysis of bone marrow precursor cells (CFU-GM and BFU-E) after treatment with WT 1 
and rabbit complement (RC)* 
CFU-GM BFU-b 
Treatment (%) (%) 
None 100 100 
RC 123 + 19 130±13 
WT1 + RC 124±1I 130±39 
WT32t + RC 113 + 26 136+18 
WT2Í + RC 4±3 0±0 
* Results are expressed as 
mean + standard deviation (two to 
five experiments), relative to the un-
treated control which was set at 
100% 
t WT 32 (IgG2a) shows OKT3 
like reactivity (Tax et al, 1983c) 
î WT 2 (IgG2a) is reactive with 
bone marrow precursor cells (Tax el 
al, 1982) and was used as a positive 
control 
DISCUSSION 
WT 1 appears to be a specific reagent for Τ lineage cells It shows its strongest reactivity on large 
thymic cells and Τ cell lines (TdT positive cells) and on PHA activated Τ lymphoblasts (TdT 
negative cells) The antibody differs from other Τ specific antibodies like OKT11 (Verbi et al, 1982), 
ΟΚΤ3 and OK.T1 (reviewed by Reinhcrz & Schlossman, 1980) both in specificity and in molecular 
weight of the recognized antigen WT 1 is similar to antibody 3A1 (Haynes et al, 1979, Haynes 
1981 ) ЗА 1 blocks the binding of WT 1 to Τ cells and therefore both antibodies appear to react with 
the same antigen 
As contrasted with 3A1, antibody WT is reactive with the majority of rhesus Τ lymphocytes 
Therefore, we could study the biological effect of WT I in a rhesus model The antibody induced a 
prolonged survival of skin allografts in three experiments Recently, the m vitro effects of another 
3A1 like antibody, designated 4A, were described (Monshima et al, 1983) When human 
lymphocytes were treated with antibody 4A and complement, the allogeneic in vitro response 
(MLC) was not decreased, and there was only a moderate reduction in the response to mitogens 
(PHA, Con A and PWM) Nevertheless, the treatment with antibody 4A plus complement 
eliminated both helper and cytotoxic Τ cell subpopulations (Monshima et al, 1983) After injection 
of WT 1 antibody, several effector mechanisms apart from complement activation may be involved 
in the elimination of WT 1 positive cells, e g phagocytosis and antibody-dependent cellular 
cytotoxicity An important aspect is that cells with low expression of 'the antigen will probably 
escape elimination, and after proliferation of these cells the balance between diiïerent Τ lymphocyte 
subpopulations (e g inducer and suppressor cells) may be altered Furthermore, Λ is conceivable 
that Τ lymphocytes are not eliminated but functionally inactivated by modulation of the WT 1 
antigen further studies will be necessary to elucidate the immunosuppressive mechanism of 
antibody WT 1 In view of the immunosuppressive activity of WT I, it is of interest that this 
antibody binds much stronger to activated Τ cells than to resting Τ cells (Tax et al, 1982, Tax et al, 
1983b) 
WT 1 appears to be useful also for the diagnosis of acute leukaemia of Τ phenotype WT 1 
invariably binds to E rosette positive T-ALL blasts, and also reacts strongly in cases of T-ALL 
which are E rosette negative, HDA-DR negative (Tax et al, 1983a) Vodinchch et al, 1983) The 
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antibody may be useful for the treatment of T-ALL (e g by removal of residual tumor cells from 
bone marrow followed by autologous bone marrow transplantation) Whenever a therapeutic 
applicat'on of a MoAb is considered, it is important to ascertain that the antibody is not reactive 
with bone marrow precursor cells The data presented show that WT 1 fulfills this condition 
In conclusion, WT 1 is a Τ specific antibody which is a useful reagent for the diagnosis of T-ALL 
and may have therapeutic application for this type of leukemia Furthermore, the antibody has 
immunosuppressive activity, and may have clinical use as an immunosuppressive agent WT 1 may 
also yield new information of Τ cell function since the immunosuppressive effect suggests that the 
WT 1 antigen is important for Τ cell function 
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INDUCTION OF NONSPECIFIC CYTOTOXICITY BY MONOCLONAL ANTI-T3 
ANTIBODIES 
J E T F M LEEUWENBERG. 1 · HERGEN SPITS,* WIL J . M. TAX.» AND PETER J . A CAPEL» 
From the'Depurimcnt of Nephrology St Radboud Hospital University t>f Nijmegen. 6500 HB Nijmegen The Netherlands. 
and the *Dwision of Immunology. The Netherland·; Cancer Institute. Plesmanlaan J21. 1066 CX Amsterdam. 
The Netherlands 
The effects of monoclonal anti-T3 antibodies on 
the effector phase of cytotoxic Τ lymphocytes (CTL) 
were studied with respect to antigen-specific and 
antigen-nonspecific lysis of different target cells. 
Anti-T3 antibodies inhibited the antigen-specific 
lysis by CTL generated in mixed lymphocyte cul­
tures (MLC), but they concomitantly augmented the 
nonspecific killing of third-party cells such a s the 
cell lines Daudi, Raji, and K562. 
This nonspecific cytotoxicity was induced by var­
ious anti-T3 antibodies, whereas antibodies reactive 
with other antigens expressed on the cytotoxic ef­
fector cells lacked any such activity. Anti-T3 anti­
bodies induced nonspecific cytotoxicity only when 
activated Τ cells, obtained by primary MLC, by re­
peated restimulation, or after cloning, were used. 
The antibodies had no effect on unstimulated pe­
ripheral Τ lymphocytes or thymocytes. The inhibi­
tion of the antigen-specific lysis and the induction 
of nonspecific lysis by anti-T3 was dose dependent, 
and both effects occurred at the same concentration 
range of anti-T3. F(ab')2 fragments of anti-T3 in­
hibited the specific lysis but were not able to induce 
cytotoxic activity, indicating that this induction is 
an Fc-dependent process. When different target 
cells were tested, only Fc receptor-positive cells 
were susceptible for this nonspecific cytotoxicity. 
Thus, anti-T3 antibodies have a dual effect on effec­
tor CTL: they inhibit antigen-specific lysis and con­
comitantly induce nonspecific lysis in an Fc-de-
pendent way. 
[n an immune response, cytotoxic Τ lymphocytes (CTL)2 
are generated that can lyse antigen-specific target cells 
in the context of the major histocompatibility complex 
(MHC) The process of Τ cell-mediated cytotoxicity con­
sists of a sequence of events starting with the recognition 
of target cells by CTL. leading to CTL-target cell adhesion. 
followed by programming of the target cell for lysis (lethal 
hit) After these steps the CTL-target cell conjugates dis­
sociate. and the lytic process proceeds independently of 
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 Abbreviations used In this paper CTL cytotoxic Τ lymphocyte MAb 
monoclonal antibody kd kllodallon PUL peripheral blood lymphocyte 
the CTL. At the stage of conjugate formation and pro­
gramming for lysis, multiple membrane elements are 
Involved, and monoclonal antibodies (MAb) directed 
against these structures can interfere with the lytic proc­
ess (1). 
Cytolysis can be Inhibited not only through blockade of 
antigen-specific receptor structures by anticlonotyplc 
antibodies reactive with a T3-assoclated heterodlmer. 
which is most likely the antigen receptor structure (2, 3). 
but also through blockade of antigens Involved In conju­
gate formation This latter type of blockade Is possible 
with anti-T8 MAb for T8* CTL. with antl-T4 MAb forT4+ 
CTL (4-7). and with anti-LFAl (8) 
Anti-T3 antibodies have been found to Inhibit cytolysis 
|9. 10) beyond the stage of conjugate formation OKT3 
Interfered with a post-recognition and adhesion step, but 
before the completion of the lethal hit (11. 12) This 
suggests that one of the components of the T3 complex, 
which consists of at least five subunits (13). Is Involved 
In signal processing leading to destruction of the target 
cell. 
In addition to the inhibition of antigen-specific lysis, 
MAb antl-T3 Induce mitosis of Τ lymphocytes, inhibit 
proliferative responses by Τ cells to soluble antigen and 
comodulatc with clonotyplc structures (2) These effects 
show that the T3 complex plays an important role In Τ 
cell function, and it Is likely that T3 Is a receptor-asso­
ciated complex of polypeptides We have prepared anti-
T3 MAb WT32 (14), similar to OKT3. Leu-4. and UCHT1 
(15). as well as WT31 which recognizes a 44-kllodaIton 
(44kd) structure from the T3 complex (16) WT31 also 
Induces mitosis. Inhibits CTL function, and Inhibits bind­
ing of other antl-T3 MAb (14) We have studied the effects 
of anti-ТЭ antibodies on antigen-specific and nonspecific 
cytolysis Here we report that anti-T3 MAb not only In­
hibit the an tige η-speci fie lysis but also Induce nonspe­
cific cytotoxicity resulting In the killing of Fc receptor-
positive third-party cells 
MATERIALS AND MbTHODS 
Preparation of lymphocyfps Peripheral blood mononuclear leu­
kocytes of normal hcalthv donors were isolated by Flcoll Paque 
(Pharmacia) density gradient cenlrlfugatlon (17| Thymocytes were 
obtained from patients undergoing corrective cardiac surgery 
Monocionai antibodies Anll-T3 MAb used were WT31 'WT32 
(14) OKT3 (Ortho Diagnostics) anti Leu 4 (Beeton Dickinson) 
UCHT1 (Beverley London) (15) SPV T3a and SPV T3b (1β| The 
antl Τβ MAb were WT81 WT82 and WTÖ5 (14) The MAb antl-
LFA, we used was SPVLi (1Θ) WT1 Is directed against the 40kd 
glycoprotein Τ cell specific antigen (19) and 7 24 against an HLA 
class I common determinant 
Generation and assay of CTL Peripheral blood lymphocytes (10е) 
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were mixed with 2000 rad Irradiated stimulator cells 105 cells/ml 
RPMl 1640 (Dutch modification) supplemented with 2 mM gluta 
mine 1 mM sodium pyruvate 50 /ig/ml Gentamicin and 20% heat 
JntU tivateri pooled human AU serum After 6 ііауь In culture at 37eC 
in the presente of 5 ^ CCb the cells were washed and either tested 
for cytotoxicity or twice rcsiimulated after С days with the original 
sllmulator cells Cytotoxicity was assessod by the standard * Cr 
relerfse assay Different concentrations of effector cells were mcu 
bated In triplicate in the presence or absence of monoclonal antl 
bodies (total volume 100 μ1| in conical bottom wells (Tlterlek Flow 
laboratories! for 30 min at 370C before being mixed with b l Cr labeled 
larflct (ells (104 cells/100 *] per well In RPMl 1640 with HFPFS 
supplemented with S**» human AU serum) After a 3 min 50 x С 
centrtfugallon the plates were incubated for З 1^ hr at 370C Then 
the plates were cenlrifugated at 550 x С lor 10 min and 100 pi of 
the supernatants were removed from each well and counted In a 
gamma counter The percentage of specific 5 ,Cr release was calru 
laled by the following formula 
experimental release - spontaneous release 
~ — • x 100 
total release In saponin - spontaneous release 
The results are expressed as the percentage of specific e i Cr release 
or as the cytotoxicity index calculated according to the formula 
c
o specific a 'Cr release with monoclonal antibody 
% specific s l Lr release in the absence of antibody 
The results are expressed as means ± standard dev lation 
CTLtloni» A CTI clone(JR2á6 18 14* ТЗ') was obtained by 
limiting dilution of Τ cells stimulated with the bps tel η Barr virus 
transformed Ü cell Une JY as described (20) 
Ceil Unes The cell lines used in this study were the В cell lines 
SB Daudt JY Rajl and RPMl 1788 the Τ cell lines СЕМ and Molt 
4 the null cell lines Nairn and REH and (he erythromyeloid cell line 
К5Ь2 
f1 (ab h fragmentó F(ab Ь fragments were prepared from WT32 
antibodies after purification by protein A Sepharose CL 4B (Phar 
mat la) chromatography After dialysis against 0 1 M sodium acetate 
buffer pH ™ 4 50 mg purified WTJ2 in an end volume of 4 ml were 
incubated with 1 mg pepsin (Boehringer Mannheim) at 37% for 18 
hr The digest was applied to a Sephacryl 400 column (Pharmacia) 
to Isolate the F(ab )3 To eliminate rontaimnatlng traces of undl 
gested IgC« the F(ab )3 was two times absorbed with proti in A 
bepharobc The percentage of intact IfiG was less than 0 03% as 
assessed In a radioimmunoassay 
Detection of Fc receptors Cells (4 χ 105) were ι neu hated with 0 5 
mg/ml heat aggregated mouse IgG purified by protein A Sepharose 
CL 4B (Pharmacia) chromatography In an end volume of 100 μΙ for 
30 min at room kmpcralure Alter washing three times with phos 
phate buffered saline containing 0 2 ^ bovine serum albumin and 
0 05 NaNj the cells were Incubated for 30 min at room temperature 
with 50 μΐ of 1/50 diluted fluorescein isothlocyanate labeled sheep 
anil mouse lg antibodies (Cappe)] This conjugate was preabsorbed 
with Sepharose coupled human lg to remove unwanted cross reac 
tlvlty 
Preparation of aggregated human IgG Human JgG (Miles Labo­
ratories 1 td ) were aggregated by heating at 63*C for 20 min at a 
concentration of 20 mg/ml 
RESULTS 
Effect of MAb antl T3 on the specific and nonspecific 
CML CTL specific for SB cells were raised from healthy 
individuals Different monoclonal antibodies were tested 
for their ability to Influence the specific lysis of SB cells 
and the lysis of different unrelated targets (Rajl K562 
Daudl) Significant Inhibition of specific lysis was ob 
served with antibodies directed against the T3 antigen 
(WT31 and WT32 final concentration 8 Mg/ml) or against 
the ΤΘ antigen {WT82 final concentration θ Mg/ml) 
When unrelated targets were tested however anti T3 
antibodies increased the nonspecific lysis significantly 
An example is shown in Figure 1 The nonspecific lysis 
was not influenced by WT82 (Fig 1) Other antibodies 
directed against T8 (WT81 WT85 OKT8) against an 
HLA class I common determinant (7-24) or against a Τ 
cell specific antigen (WT1) also did not influence the 
V. 5 1 Cr re lease 
l o r y * erti SB Raj К5Б2 Ooud 
Figure J Effect of antl ТЭ (WT31 and WT32) and antl T8 (WT82) on 
the specific (target = SB1 and nonspecific (target - Rajl К^бг Daudl] cell 
mediated lympholysls MAb was added to the effector cells at a final 
concentration of 8 jig/ml 30 min before the addition of the "Cr labeled 
target cells The target to effector ratio was 1 10 Numbers given are 
means ± SD of the triplicate values 
C y i o O K с i y n d e x 
' " ' S · ' « " SB Roi K562 Ο Λ Ο 
rtumbfffot N18 N.15 N В и Я 
Figure 2 The combined data are shown from a number (N) of experl 
ments In which different CIL specific for SB cells are tested for their 
ability to kill different targets In the presence or absence of MAb anti T3 
(WT31andWT32 final concentration 8 pg/ml) Each bar represents the 
percent of lysis in the presence of MAb percent of lysis without MAb 
(cytotoxicity index] The target lo effector ratio was 1 10 
nonspecific lysis (data not shown) SB specific CTL were 
raised from 18 different donors by a primary mixed lym 
phocyte culture (MLC) of an IILA int ompatible combina 
tion Part of the CTL were tested against nonspecific 
targets and In all cases antl T3 augmented the nonspe­
cific lysis of the targets Rajl К S 62 and Daudl but In­
hibited the lysis of SB cells (Fig 2) 
induction of cytotoxicity by α panel oj anti T3 MAb 
To investigate whether all antl T3 MAb had the capacity 
to augment nonspecific lysis and to rule out a particular 
effect of a given antibody different antl T3 antibodies 
were Investigated CTL spet ific for SB cells {twice stlm 
ulated) were tested against SB and Daudi cells with the 
following antibodies OKT3 Leu4 UCHT1 SPV-T3d and 
SPV T3a WT31 and WT32 WT82 and WT1 were In-
35 
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eluded as controls The results of this experiment with a 
target to effector ratio of 1 10 are shown In Table I The 
other ratios tested were 1 3 and 1 30, and at all ratios 
the same pattern was observed All antl-T3 and anti-Tfi 
antibodies Inhibited the specific lysis of SB but only antl-
T3 enhanced the nonspecific lysis WT82 (anli-T8| and 
WT1 had no effect on the nonspecific lysis 
Titration of anti T3 To determine the optimal concen­
tration of anti-T3 for inhibition of the specific lysis and 
for induction of nonspecific killing of Daudl cells by SB-
specific CTL (twice stimulated), different concentrations 
of WT32 were tested ranging from 0 1 to 200 i<g/ml A 
representative example Is given at a target to effector 
ratio of 1 10 In Figure 3, and the results demonstrate 
that Inhibition as well as Induction of nonspecific cyto-
TABLE ι 
The eifert of MAh on the specific and nonspecific lysis' by CTL anti 
SB tuice stimulated with Irradiated Ы) cells 
Target Cells 
MAb» SB Oaudl 
OKT3 
antl L£U 4 
WTJI 
WTI2 
IJCHTI 
S P V T M 
Ы> T í a 
WTS2 
W T I 
% Lysis 
33 
2 0 
12 
2 0 
5 
17 
5 
4 
2 5 
3 3 
% Inhlblllon' 
3 9 
6 1 
3 9 
8 4 
4 8 
4 
8 7 
2 4 
0 
% Lyn» 
12 
3 0 
2 9 
1 3 
3 4 
3 0 
3 5 
2 4 
11 
12 
% Stimula 
_ 1 5 0 
141 
175 
184 
150 
191 
100 
0 
0 
" Th« (argel lo effector ratio was 1 10 
"The effector cells were incubated with the MAb 30 min before the 
addition of the 5lCr labeled target cells The final concentration of mon 
©clonal anlibodi« In the assay »ds θ д£/тІ for WTI WT3I WT32 
\ Тв2 2д(УтІГогиСНТІ ЪР T3d SP V Τ За and 1 μ&ΛηΙ for anil Leu 
4 The commercially available OKT3 was added after dialysis at a final 
dilution of 1/100 
„ % lysis + Mab 
' P e r c e n t of Inhibition is expressed as 100% - — - i χ 100% p
 % lysis - Mab 
" Percent of stimulation Is expressed a s 100% - —— ж 100% 
% lysis - Mab 
- 100% 
Cytotoxcity index -
- i 1 1 1 1 1 1 1 1 1 1 r*-r-> 
0 1 0Ü 16 6 5 2 5 5 100 ¿OO 
anli T3 conceniralioo ( jug /ml > 
h tqure 3 Dose-dependent Inhibition of specific killing and stimulation 
of nonspecific killing by antl T Ì (WT32| with the use of an SB-specific 
CTL twice stimulated The target to effector ratio was 1 10 
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toxicity are dose dependent For most of the experiments 
8 μg antl-T3/ml was chosen as the final concentration 
Reactivity of unstimulated peripheral blood lympho­
cytes (PBL) and thymocytes To Investigate under which 
conditions Τ cells can be stimulated to nonspecific killing 
by anti-T3 antibodies, PBL from nine different donors 
were isolated These PBL were tested directly for their 
killing capacity of SB. Rajl, Daudi. and K562 cells In the 
presence or absence of antibodies The monoclonal anti­
bodies used in the assay were WT31 and WT32 (antl-T3). 
WT81 and WT82 (antl-T8) and WTI In a final concen­
tration of 8 Mg/ml The combined results are shown In 
Figure 4 WT31 was not able to Induce kill of targets by 
freshly Isolated PBL from nine different donors, and 
comparable results were obtained with WT32 The other 
MAb (WT82. 7-24. WTI) tested also had no effect (data 
not shown) When these PBL were stimulated with SB 
cells and tested at day 6. antl-T3 inhibited the specific 
lysis of SB cells and Induced nonspecific lysis comparable 
with the results given in Figure 2 (data not shown) When 
thymocytes were Incubated with anti-T3 (anti-Leu-4 and 
SPV-TSd), no nonspecific lysis was Induced by this treat­
ment (data not shown) 
Fc dependency of the induced nonspecific cytotox­
icity To test whether the Fc fragments of anti-T3 anti­
bodies are Important in the induction of nonspecific lysis, 
Ffab'b fragments were prepared from WT32 and lested 
in a cell-mediated lympholysis Less than 0 03% of Intact 
antibodies were present In this preparation as measured 
In a radioimmunoassay specific for Fc fragments The 
F(ab')2 preparation had on a molar base a similar antigen-
binding capacity as Intact WT32 as was tested by Im­
munofluorescence When tested with SB-specific CTL. 
the inhibition of the specific lysis of SB cells by Flab'h 
fragments was In the same range as by WT32 on a molar 
base (Fig 5) The ability of F(ab')2 fragments to induce 
nonspecific lysis was tested by using SB-specific CTL 
with the unrelated targets Rajl Daudi, and K562 cells 
The results obtained with 8 Mg WT32 and a similar con­
centration of WT32-F(ab')2 (S^g/ml) are given in Figure 
6, and clearly show that the Induction of nonspecific 
lysis Is Fc dependent At other target to effector ratios 
(1 3 and 1 30) the same pattern was observed These 
findings suggest the Involvement of Fc receptors on the 
target cells In this process, and therefore a panel of 
different target cells was tested for the presence of Fc 
receptors and their susceptibility to nonspecific lysis The 
% 5 t r releas« 
largel evil SB floji Daudi KS62 
Figure 4 The effect of MAb antl T 3 (WT32| on the cytolysls of differ­
ent targets (SB Rajl Daudl KS62) by freshly Isolated PBL Each bar 
represents the mean percentage of lysis of nine different experiments 
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, 5'Cf release TABLE II 
The effect of aggregated human IgG on the antt T3 Induced lysis" by 
10 100 1000 
>jganti Тз/т( 
FI9ure5 Comparison of the еГГесіа оГ Intact anti ТЗ (WT32) and 
F|ab )з fragments of WT32 on the specific lysis of SB cells by CTL specific 
for SB at a target to effector ratio of 1 30 The shaded bar represents the 
percent ol lysis of SB cells without addition Ol antibody 
20 10 E0 
'/. 51 Cr release 
Figure 6 Effect of antt T3 |WT32) and WT32 F(ab la on the nonspe 
clflc lysis of RaJI Daudl and K562 cells by CTL twice stimulated with 
Irradiated SB cells at a target to effector ratio of 1 IО 
presence of Fc receptors was determined on different 
target cells by using heat-aggregated mouse IgG, and the 
following results were obtained the percentage of Fc 
receptor-positive cells was >90% for Daudl, >90% for 
K562. and 50% for RaJI The other cells tested—RPMI 
1788. СЕМ. Molt-4. REH. and Nairn—were mouse IgG Fc 
receptor negative CTL specific for SB cells were Incu­
bated with β »»g/ml WT31 and WT32 and subsequently 
were tested on different target cells mentioned above 
Nonspecific antl-T3-lnduced cytotoxicity was only ob­
served with the Fc receptor-positive cells Daudl, K562, 
and RaJI no Increase of cytotoxicity In the presence of 
antl-T3 was obtained with the Fc receptor-negative cells 
If the Fc receptors on the target cells are Involved In 
this process, then binding of aggregated IgG to these 
receptors should Influence the antl-T3-lnduced cytotox­
icity Therefore, the target cells Daudl and RaJI were 
prelncubated with aggregated human IgG before the ad­
dition to SB-specific CTL The results In Table II show 
that the cytotoxicity Induced by WT32 (anti ТЗ) Is in­
hibited by the pretreatment of the target cells with aggre­
gated human IgG 
Induction of nonspecißc cytotoxicity ina Τ cell clone 
P r r t r a t m e n t of 
Target Celle* 
Aggregated h u m a n IgG 
SS spectßc CTL 
Targel 
% Lysle Daudl 
- /тэг 
12 34 
13 15 
Celle 
% Lysis Rajl 
— W T 3 2 1 
2 15 
2 2 
0 T h e largrt to effector ratio was I 10 
"The target cells (10* rells/ml) were prelncubated for 15 min al room 
temperature with heat aggregated human IgG (2 mg/ml) and diluted to 
the appropriate cell concentration (105 cells/ml) before addition to the 
CTL 
cThe effector cells were Incubated with anil T3 (WT32 θ Mg/ml) 30 
min before the addition ol the eiCr labeled target cells 
•amiTj Ftab I j 
ffagmuMs 
'/ю 
largel/effector rato 
Figure 7 Effect of anti T3 MAb (WT32) on the specific lysis of JY and 
the nonspecific lysis ol RaJI K562 and Daudl by a Τ cell clone |JR 2 26) 
To rule out the possibility that the cytolysls Induced by 
antl-T3 antibodies was caused by an unknown synergis­
tic effect of different cells present In bulk Τ cell cultures, 
a cytotoxic Τ cell clone with a T4* T3* phenotype. reactive 
with JY cells, was tested At different target to effector 
ratios (1 1 and 1 10) killing of the targets K562. Daudl. 
and RaJI was absent Addition of WT31 or WT32 (8 /ig/ 
ml), however. Induced nonspecific lysis of these targets, 
whereas the killing of the stimulatory cell JY was In­
hibited by antl-T3 (WT31 as well as WT32) Addition of 
Flab'k fragments of WT32 (5 ^ g/ml) did not Induce lysis 
of K562, Daudl, or RaJI cells, but It blocked the specific 
lysis of JY cells (Fig 7) 
The lysis of target cells by CTL Is a multiple step 
process In which antigen Is specifically recognized In the 
context of MHC Various differentiation antigens are in­
volved In this process, and monoclonal antibodies against 
these membrane structures can inhibit the lytic process, 
each at different levels The Inhibition of antlgen-speclf 1c 
cytolysls by anti-T3 antibodies is at the level of program­
ming for lysis after the adhesion step Antl-T3 antibodies 
have multiple effects on Τ cell function (13), and it Is 
most likely that the T3 complex plays a pivotal role In 
signal processing The T3 complex consists of a group of 
proteins associated with a 44 to 49kd clonotyplc hetero-
dlmer (13), which Is probably the Τ cell receptor Our 
findings confirm that antlgen-speclflc lysis by CTL is 
inhibited by different monoclonal antibodies, including 
antl-T3 antibodies (9, 10) Apart from the Inhibition of 
the antigen specific lysis, however. anti-T3 antibodies 
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Induced an increase in the lysis of nonspecific targets 
when CTL obtained from MLC were used This effect was 
consistently observed with CTL from 1 θ different donors 
sltmulated with the В cell line SB CTL raised tn MLC 
with different HLA mismatched leukocytes used as stim 
ulators also mediate nonspecific cytotoxic activity in the 
presence of anti T3 antibodies (data not shown) This 
Indicates that the increase in the amount of nonspecific 
lysis by anti TJ is a general phenomenon of CTL that is 
independent of the stimulator cell used to activate the 
CTL 
Seven different anti T3 MAb with different subclasses 
and affinities were tested and all antibodies induced a 
highly significant increase in nonspecific lysis whereas 
three different antl 18 antibodies anti HLA А В and С 
and WTI antibody were unable to enhance nonspecific 
cytotoxic activilles These data rule out that nonspecific 
factors present In the antibody preparations are respon 
sible for this effect and also show that the T3 antigen is 
invoked in this process Various subclasses were tested 
as well We conclude that anti T3 independent of its 
subclass induces a process by which a CTL becomes 
cytotoxic for third parly cells 
Resting Τ cells and thymocytes were not susceptible to 
the induction of nonspecific lytic activity by anti T3 as 
was shown in Figure 4 The natural killer activity present 
in these preparations as defined by the lysis of K562 as 
target cells was nol altered by anti T3 Stimulated Τ 
cells however had become susceptible to this anti T3 
induced lysis when CTL were harvested at day 6 This 
could mean that the lytic capacity of resting Τ cells is not 
yet functional but develops In time after stimulation 
When cell lines were established by weekly restimula 
lions this susceptibility for induction of cytolysisb} anti 
TT remained Bulk cultures of CTL or cell lines are in 
homogeneous cell populations and some unknow η s> η 
ergistic effect between different cells might be responsi 
ble for our findings To exclude this possibility a Τ cell 
clone was tested When anli T3 was added to this clone 
target cells that normally were not affected at all by the 
Τ cell at different effector to target ratios were lysed 
These data were consistent when a series of different Τ 
cell clones were used and even noncytotoxlc proliferating 
Τ cell clones became cytotoxic by antl T3 Incubation (21 ) 
The stimulatory concentration of antl T3 was In the same 
range as the inhibitory concentrations that inhibited the 
antigen specific killing by anti T3 The mechanism of 
this nonspecific lytic activity however is unknown but 
the results obtained with Ffab )э fragments indicate that 
the Fc portion is involved m this process The fact that 
only target cells bearing Fc receptors for mouse IgG can 
be lysed non specifica Ну suggests that cross linking of T3 
on the effector cell bv Fc receptors might be Involved in 
the triggering of a nonspecific lytic machinery in the 
effector cells The antl T3 mediated cytotoxicity can be 
inhibited by aggregated human IgG which also supports 
the in voh ement of Гс receptors in this process The antl 
T3 Induced mitosis of Τ cells requires cross linking of T3 
via tc receptors (22) and Immune complexes are also 
inhibitor) in this process This parallel with our findings 
of the indut lion of nonspecific cytotoxicity by anti T3 
antibodies is tempting although the concentration of 
anti T3 necessary for the induction of mitogenesis is 
much lower than the concentration to Induce cytotoxic 
ity The observed increased Ca2* Influx induced by anti 
T3 in T3 positive cells (23) confirms that T3 plays a 
pivotal role in Τ cell activation and it is conceivable that 
T3 cross linking might Indeed trigger multiple processes 
in Τ cells 
In view of the Induction of nonspecific lysis one would 
expect that Inhibition of specific lysis by antl T3 MAb is 
counterbalanced by this process But if the presence of 
Fc receptors on the target cell is of importance then the 
antigen specific target cells used will Influence the out 
comcof the Inhibition by anti T3 Indeed the SB and JY 
cells w hlch are Fc receptor negative for mouse IgG ( an 
be totally Inhibited by anti T3 but the inhibition of the 
antigen specific lysis by anti T3 with Fc receptor positive 
Raji cells used is less pronounced (data not shown) In 
our study all targel cells used were T3 negative as was 
confirmed by immunofluorescence also the Τ cell lines 
СЕМ and Molt 4 which are derived from Τ cells early in 
the differentiation pathway lacked T3 expression 
Therefore the antl Γ3 antibodies could only react with 
the effector cells used and Induce a nonspecific cytotox 
icity This effect is only observed with activated Τ cells 
and not with resting Τ cells Besides that already known 
multiple effects of anti T3 on Τ cells such as an in 
creased Ca2 + influx induction of mitosis inhibition of 
antigen specific proliferation and inhibition of antigen 
specific lysis our studies add another functional aspect 
of T3 in Τ cell activity namely the induction on nonspe 
ciflc cytotoxicity The mechanism of this process is Fc 
dependent and most likely involves cross linking of antl 
T3 by Fc receptors on the target cells 
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Antigen-specific cytotoxic Τ cell and antigen-specific 
proliferating Τ cell clones can be induced to cytolytic 
activity by monoclonal antibodies against T3 
Ή is a human differentiation antigen expressed exclusively on mature Τ cells In this 
study it is shown that anti-T3 monoclonal antibodies, in addition to their capacity to 
induce Τ cells to proliferate, are able to induce amigen-spcufic cytotoxic Τ lympho­
cyte clones to mediate antigen nonspecific cytotoxic activity It is furthermore shown 
that ami T3 reagents arc able to trigger lytic activity in Τ cell clones characterized as 
noncylotoxic antigen-specific proliferating I cells The data presented indicate that 
perturbation of ТІ can trigger the lytic machinery in cytolytic as well as noncytolytic Τ 
cell clones 
1 Introduction 
Τ cell activation requires the interaction between antigen and 
products of the major histocompatibility complex (MI 1С) on 
the antigen-presenting cell and the Τ cell receptor for antigen 
on the Τ cell The activation of Τ cells by antigen can be 
mimicked by monoclonal antibodies (mAb) against the Τ cell 
antigen TI [1-4] This is understandable in view of the findings 
that the Τ cell receptor for alloantigcn [4 5) and for antigen 
plus a self MHC product |6] are disulfide-linked heterodimcrs 
with a molecular weight of 90 000 which are associated with 
nonvanable proteins of the T3 complex [7, 8] In this study we 
demonstrate that in addition to the induction of Τ cell prolifer­
ation [1, 2) and inhibition of antigen specific cytotoxic Τ cell 
activity [9-Π] anti-T3 reagents arc also able to induce non­
specific cytotoxic activity, even in antigen-specific proliferative 
Τ cell clones 
2 Materials and methods 
2.1 Γ cell clones and cell lines 
The characteristics of the Τ cell clones used in this study are 
shown m Table 1 The alloreactive cytotoxic and proliferating 
Τ cell clones used were isolated from Τ cells of donor HG 
(HLA-A2 w24, B40,w44, DRw6,7), I iv(HLA-2 w31,Bw44, 
w60, DIU,-), and JR (HLA-Aw23, w29, B7 7, DRs) which 
were stimulated with cells of the Epstein-Barr virus (EBV)-
transformed В cell line J Y as described previously [14] 
Cytotoxic Τ lymphocyte (CTL) clone HG-61 (TVT4-T8") 
lyses 30% of B7. 50% of B40 and 100% of B27 (subtype k)-
beanng target cells [IS] Its reactivity is blocked by the class I 
МНС-specific antibody W6.'32 CTL clone Uv 8(T3'T4"T8-) 
recognizes 90%· of all cells bearing B7 Its specificity, as far as 
tested, is identical to [hat of CTL clone HG-31. which has 
been analvzed previously to be specific for HLA-B7 [16] The 
activity of CTL clone Liv-8 was blocked with \V6.12 The CTL 
clone JR-2-26 killed exclusively cells expressing IILA-DRw6 
[17] Its activity was blocked by the mAb SPV-L3, which rec­
ti 4580] 
Correspondence. Hcrgcn Spits Division of Immunology The Nether­
lands Cancer Insntiite. Plesmanlaan 121 1066 CX Amslerdam NL 
Abbreviations: CTL: Cytotoxic Τ lymphocyte PTL Proliferalmg Τ 
lymphocyte EBV' Epstcin-Вагг virus HPH: Helix pomatia hemo-
cyamn BSA: Bovine scrum albumin TT: Tclanus toxoid MHC: 
Major histocompatibility complex mAb: Monoclonal antibodv(ics) 
ognizes a monomorphic determinant present on HLA-DC 
molecules indicating that JR-2-26 recognizes an HLA-DC 
product [17] The proliferating Τ lymphocyte (PTL) clone JR-
2-3 proliferated only with JY cells and with most but not all 
cells expressing the IILA-DRw6 specificity (H Spits, unpub­
lished) The PTL clones IIG-49 and HG-120 proliferated after 
stimulation with irradiated JY This proliferation could be 
blocked with the anti-HLA-DR mAb 05/13 (results not 
shown) The specificity of these clones was not investigated 
further The clones MK-2. MK-6, MK-9 and MK 21 which 
were all of the T4~T8 phenotype were derived from Τ cells of 
donor MK(HLA-A2,29,Bw44,w22, Cwl. DRS 7) who was 
immunized intramuscularly with 1 mg Helix pomaiia hemocy-
anm (IIPH, kindly provided by Drs Torcnsma and The, 
Department of Clinical Immunologi of the State University. 
Groningen, The Netherlands) Fourteen days after immuniza­
tion l(r jjcripheral blood lymphocytes/ml were stimulated m 
vuro with 50 μg/ml HPH Six days later the cells were cloned 
by limiting dilution at one cell cverv 2 wells using irradiated 
(4000 rds) autologous and allogeneic lvmphocvtes(10(' ml) and 
irradiated (5000 rds) JY cells, 10 jigiml HPH and 5% (v'v) of 
an mtcrleukin 2 (IL2)-containing supernatant When neces­
sary, Τ cell clones were subcloncd using the same procedure 
Cloning and subcloning of the cells was performed in flat-
bottomed 96-well microliter plaies (no 1S96 Costar Cam-
bndge, MA) Proliferating cells became visible at day 10-14 
Table I. Summary of the properues of the Τ cell clones used in ihis 
study 
Τ cell clone 
HG-49 
HG-61 
HG-12Í) 
лк-г-з" 
JR-2-26 
Liv-8 
MK-2 
MK-6 
MK-9 
мк-гі
0 
Phenotype 
T4*T8-
T4 T8' 
Т4~Г8-
T4*T8 
T4T8-
T4-T8* 
Τ4*Τβ 
T4*1ï-
T4-T8-
Т4 4ТГ 
Function 
PTL1' 
CTL« 
PTL 
PTL 
CTL 
CTL 
PTL 
PTL 
PTL 
PTL 
Specificity 
associated with 
HLA-B27k 
-HLA-DRw6 
HLA-DRw« 
HLA-B7 
HPH 
HPH 
_ 
HPH 
a) Proliferating non-CrL clone 
bj CTL clone 
c) The PTL clones JR-2 3 and MK 21 were derived from subcloning 
the original JR-2 Í and MK 21 parent clones 
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and were transferred to 24-well plates (no. 3424. Costar) and 
expanded by stimulating the clones once or twice in 14 days 
with the feeder cell mixture which was used to clone the cells 
Every 3 days the cultures were split and fresh medium contain­
ing 5% (v/v) of an IL 2-contaming supernatant [14] was added. 
The cloned Τ cells were used in the cytotoxic assays (vide 
infra) 9 days after stimulation with the feeder cell mixture. 
Cloning procedure and tissue culture were earned out in 
serum-free Iscove's medium supplemented with 2xlO" 5 M 
ethanolamin {Merck, Darmstadt, FRG), 35 μg/ml transferrin, 
5 μg/ml insulin and 2-5 mg/ml bovine serum albumin (BSA; all 
three from Sigma, St. Louis, MO) and 1% (v/v) of a dispersion 
of lipids extracted from human plasma [14]- The EBV-trans-
formed В cell lines J Y and Laz475 (kindly provided by Dr. H. 
Lazarus, Dana-Farber Cancer Center, Boston, MA) were cul­
tured in serum-free Iscove's medium. 
2.2 mAb 
The mAb anti-Lôu-4 (IgGi), which recognizes the Τ cell anti­
gen T3 [18] was obtained from Becton Dickinson (Mechelen, 
Belgium); mAb SPV-T3b (IgG
: a
). SPV-L1 (IgGO and SPV-T8 
(IgGi) which recognize T3, LFA-1 and T8, respectively, have 
been described previously [19, 20]. SPV-L3 (IgG2
a
) recognizes 
a nonpolymorphic determinant present on HLA-DC products 
[17] W6/32 (IgG2
a
). obtained from Sera Labs., Crawley 
Down, GB. recognizes a determinant present on all HLA-A, 
В and С molecules [21]. In some experiments the mAb were 
partly punfied by precipitation at 45% (NH^SOj saturation, 
followed by dialysis against 2 volumes of phosphate-buffered 
saline. 
2.3 Cytotoxicity assays 
The assay measuring inhibition or induction of cytotoxic activ­
ity was carried out as follows: the Τ cell clones were preincu-
bated for 30 mm at 37 0C in U-shaped microtiter wells with 
mAb in 50 μΐ Iscove's medium supplemented with 0.25% 
BSA. Then 50 μΐ containing 10' s,Cr-labeled target cells were 
added. The plates were centnfuged at 50 x g for 5 mm and 
incubated for 4 h at 37 0C and 5% CO2- The percentage 
cytotoxicity was calculated as described previously [14]. 
2.4 Measurement of proliferation 
The antigen specificity of cloned Τ cells was determined by 
measuring the proliferation of 5 χ 103 cloned Τ cells/well in the 
presence of 2 Χ 101 autologous monocytes/well and various 
antigens or irradiated (5000 rds) JY cells (2 x IO1 cells/well) 
These tests were carried out in flat-bottomed 0 2 ml wells 
(Costar) in serum-free Iscove's medium Three days later 
0,4 μΟ (= 14.8 kBq) [3H]dThd was added and after overnight 
incubation, the cultures were harvested on glass fiber filter 
strips After drying, the filters were counted in a liquid scintil­
lation counter. 
3 Results 
3.1 Induction of antigen nonspecific cytotoxicity by anti-T3 
mAb 
The effect of two different anti-T3 antibodies, anti-Leu4 and 
SPV-T3b, on the cytotoxic activity of two CTL clones, Liv-8 
Induction of cytotoxicity by monoclonal antibodies against T3 
and HG-61, was investigated. Table 2 shows that the cytotoxic 
activity of CTL clone HG-61 against JY cells was blocked by 
both anti-T3 antibodies. The cytotoxicity, however, of another 
CTL clone Liv-8 was not or only minimally affected, when 
compared with the effect of the anti-T3 antibodies on the 
activity of HG-61. The capacity of the anti-T3 reagents to 
block the activity of HG-61 and Liv-8 could not be enhanced 
by increasing the concentration of the antibodies (results not 
shown). Furthermore, it was found that these two clones HG-
61 and Liv-8, which were not cytotoxic for the В cell line 
Laz 475, could kill this line efficiently in the presence of the 
anti-T3 mAb (Table 2). Although the induction of cytotoxicity 
by anti-T3 mAb showed some degree of variation, the 
strongest cytotoxic activity was induced in CTL clone Liv-8. 
The antigen-specific cytotoxicity of Liv-8 against JY cells was 
minimally blocked by the anti-T3 reagents. In contrast the 
activity of HG-61 was blocked well by the anti-T3 antibodies, 
but these reagents were less effective in inducing cytotoxicity 
of HG-61 against Laz 475 Anti-T3 antibodies did not only 
induce cytotoxicity in T8+ CTL clones, but also in the T4+ 
CTL clone JR-2-26, which is specific for a HLA-DC product 
present on HLA-DRw6-positive cell lines (Table 3). 
Moreover, Table 3 shows that the antibodies against other cell 
surface antigens, which are involved in cytotoxic activity, SPV-
Ll, SPV-T8, OKT4a, W6/32 and SPV-L3, are unable to induce 
Table 2. The effect of two anti-T3 mAb on the cytotoxic activity 
mediated by the CTL clones HG-61 and Liv-811 
mAb % Cytotoxicity 
Target cell 
JY Laz 475 
Uv-8 HO-61 Liv-8 HG-61 
None 59 85 3 3 
Anti-Lcu4 54 55 63 27 
SPV-T3b 42 37 50 14 
a) The commercially available stock solution of anti-Leu-4 (100 μg/ 
ml) was diluted 1:100 to give a final dilution of 1 μ^ηιΐ, whereas 
SPV-T3b was used as ascites in a final dilution of 1: 100 The Είΐ 
ratio was 5 I 
Table 3. The effect of mAb on the cytotoxic activity of HG-61 and 
Liv-8 and JR-2-26 against the В cell line Laz 475a) 
mAb 
None 
Anti-Leu4 
OKT-tA 
SPV-T8 
SPV-L1 
W&32 
SPV-L3 
_ 
T3 
T4 
T8 
LFA-1 
HLA-
A ; B,C 
HLA-DC 
HG-61 
(T4-T8*; 
4 
40 
0 
v
6 
0 
2 
9 
% Cytoto»city 
Uv-8 
1 ( Т 4 Т Г ) 
2 
54 
4 
0 
4 
2 
4 
JR-2-26 
(T4*T8) 
6 
30 
13 
3 
2 
4 
6 
a) The concentrations of added antibodies were 2 μg/mI. except SPV-
T8 which was added as a 1/100 dilution of ascites The E/T ratio 
used was 5:1 
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cytotoxicity in these CTL clones, indicating that the cytotoxic­
ity inducing capacity of anti-T3 antibodies is a specific effect. 
3.2 Induction of cytotoxic activity in noncytotoxic Τ cell clones 
Since the ability to lyse target cells is thought to be absent in 
noncytotoxic antigen-specific proliferating Τ cells, anti-T3 
antibodies should not be able to render such Τ cell clones 
cytotoxic. However, to our surprise anti-Leu-4 was able to 
trigger significant cytotoxicity in clones characterized as anti­
gen-specific proliferating Τ cells- In Table 4 it is shown that 
2 μg/ml anti-Leu-4 induced cytotoxicity in four noncytotoxic 
T 4 + clones which were derived from Τ cells of a donor 
immunized with the antigen H P H . Three of these clones pro­
liferated specifically in response to HPH in the presence of 
autologous monocytes, but not in response to the control anti­
gen tetanus toxoid (TT, Table 4). Note thai one of these 
clones was subcloned (MK-21). Anti-Leu-4 also triggered 
cytotoxicity in the Τ cell (sub)clone JR-2-3, which proliferates 
Table 4. Anti-Leu-4 induces noncytotoxic antigen-specific Τ cell 
clones to express cytotoxic activity against Laz 475 cells 
in response to irradiated JY cells in the absence of exogenous 
IL 2, but which was not cytotoxic for J Y or for other target 
cells, including K562 cells which are highly sensitive for 
natural killer-like activity (results not shown). However, anti-
Leu-4 did not trigger cytotoxic activity in all T3* cells, since 
two T 3 + PTL clones, HG-49 and HG-120, were not cytotoxic 
in the presence of anti-Leu-4 (Table 4). 
3.3 The effect of m Ab against LFA-1 and T8 on the anti-T3-
induced cytotoxicity 
The cytotoxiaty induced by anti-Leu-4 was strongly blocked 
by SPV-L1, an antibody which recognizes human LFA-1 
[19, 20] (Table 5), but not by SPV-T8 which is an antibody 
against T8 [19] Since LFA-1 is thought to be involved in adhe­
sion between the effector and the target cell [22], this finding 
suggests that cell-cell contact is required for the anti-T3-
induced cytotoxicity to occur This notion is supported by the 
finding that E D T A which blocks conjugate formation [23] also 
inhibits the killing activity induced by anti-Leu-4 (results not 
shown) Furthermore, these results exclude the possibility that 
the target cells are lysed by a soluble lymphotoxin in the ab­
sence of effector-target cell binding 
Τ cell pHldThd"' incorporation 
clone (cpm χ IO-3) after stimulation 
with 
None HPH" TT11 
(1 (ig/ml) (15 Ш 
ml) 
HG-61 -
JR-2-3 1 
MK-2 0.9 
MK-« 0 5 
MK-9 0.9 
MK-21 0.6 
HG-49 0.5 
HG-120 0.8 
N T ' 
NT 
11 
10 
Π 5 
18 
NT 
NT 
NT 
NT 
0.5 
0.6 
0.5 
0.6 
m 
NT 
• 
i
JY 
NT 
6 
NT 
NT 
NT 
NT 
4 
8 
Function % 
Cytotoxiaty" 
Me- Anti-
dium Leu-4 
Cytotoxic 2 27 
Noncytotoxic 3 36 
Noncytotoxic 3 32 
Noncytotoxic 2 28 
Noncytotoxic 2 40 
Noncytotoxic 4 38 
Noncytotoxic 5 8 
Noncytotoxic 0 4 
a) |5H]dThd = Tntiated thymidine. 
b) Determined at an Ε Τ ratio of 10:1. 
c) 1 ц ^ т і 
d) 15 LF/ml 
e) NT = Not tested 
TableS. The effect of antibodies against LFA-1 and T8 on the 
cytotoxic activity of clone HG-61 and Liv-8 against Laz 475 m the 
presence of anti-Leu-^1 
CTL 
clone 
HG-61 
Liv-8 
% Cytotoxicity ш the presence of 2 ц§/т1 antt-Leu-4 
Control mAb Reciproca] dilution of ascites 
added 50 200 800 
'25 
40 
SPV-L1 5 
SPV-T8 33 
SPV-L1 
SPV-T8 
4 
50 
7 
32 
13 
53 
10 
30 
17 
43 
a) The cytotoxic activity of clone HG-61 and Liv-8 against Laz 475 in 
the absence of anti-Leu-4 was 2 and 1%. respectively The EÍT 
ratio used was 5:1 
4 Discussion 
Two novel points emerge from the study presented in this 
study. First, perturbation of T3 by anti-T3 mAb results in the 
induction of antigen nonspecific cytotoxic activity, and second, 
anti-T3 reagents may trigger a cytolytic mechanism in Τ cell 
clones characterized as noncytotoxic antigen-specific pro­
liferating Τ cells. 
Although only a small number of clones was analyzed here, 
the observations suggest that anti-T3 induces cytotoxicity in Τ 
cell clones irrespective of whether the Τ cell clone was cytotox­
ic or not, since noncytotoxic antigen-specific proliferating Τ 
cell clones became cytotoxic in the presence of anti-Leu-4-
Nevertheless not all Τ cell clones were induced by anti-T3 
antibodies, since two proliferating Τ cell clones could not be 
rendered cytotoxic by anti-T3. Since the mechanism of the 
anti-T3-induced cytotoxicity is not understood, we do not 
know why some clones are rendered cytotoxic by anti-T3 anti­
bodies and others not. It is possible that the clones, which can 
be triggered to express cytolytic activity, represent a subset of 
Τ cells which is different from those which cannot be triggered 
by anti-T3 reagents On the other hand, it may be that PTL 
clones can only be induced to mediate cytolytic activity at a 
certain stage of maturation. It has been reported by several 
groups that antigen-specific CTL clones acquire иошрбсШс 
cytotoxic activity after a prolonged period of culture [24-26]. 
This phenomenon has been termed aged killer activity by 
Simons et al. [26], and indicates that "aging" of Τ cell cultures 
may result in changing properties of the Τ cells [27]. Further­
more, it has been reported that Τ cell clones mediating allo-
specific cytotoxicity may also have proliferative capacity as 
well as helper activity for В cell differentiation [28, 29]. Thus 
there appears to be an overlap between antigen-specific 
cytotoxic and proliferating capacity. Such a conclusion can 
also be drawn from the findings of Fleischer who reported that 
proliferating clones specific for virus in the context of self 
class Π М Н С products acquire cytotoxic activity with the same 
specificity after prolonged culture of the Τ cell clones [30] 
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However, the cytotoxicity induced by anli-T3 antibodies is not 
dependent on the age of the Τ cell clones, since the clones HG-
49 and HG-120, which could not be induced to become 
cytotoxic, were of the same age as the inducible clones HG-61 
and MK-9 In addition, cytotoxicity could be induced both in 
relatively young clones (less than 4 weeks in culture) as well as 
in relatively old clones (11 weeks in culture) 
Since it has been found that anti-LFA-1 antibodies block cell­
ed! adhesion in the murine [22] as well as m the human system 
(H Spits, unpublished), the observation that SPV-L1 inhibits 
the anli-T3 induced cytotoxicity indicates that cell-cell contact 
is required It is not yet understood how contact between the Τ 
cell clone and the target cell in the absence of specific antigen 
recogmtion is established Recently it has been found that 
F(ab')2 fragments of anli-T3 antibodies, which are thoroughly 
depleted of intact antibodies, fail to induce nonspecific 
cytotoxicity, whereas they effectively block antigen-specific 
cytotoxic activity (P Capel, personal communication) This 
suggests that binding of the Τ cell clone to the target cell 
involves binding of the target cell to the Fc part of the anti-T3 
antibody bound to the effector cell 
The mechanism by which anti-T3 antibodies induce cytotoxic­
ity is presently unclear It may be possible that T3 is directly 
involved in the triggering of the lytic machinery This interpre­
tation is supported by the observations that anti-T3 reagents 
block ant ige η-specific cytotoxicity not by preventing the for­
mation of stable conjugates, but in a later stage of the 
cytotoxic reaction [12, 13] The fact that the receptor for 
alloantigen is associated with the T3 complex [4, 8] raises the 
possibility that one of the components of the T3 complex con­
verts the signal provided by the binding of antigen to its recep­
tor to trigger cytotoxicity It seems that binding of anti-T3 
antibodies to their determinants on one hand prevents the 
transduction of the cytotoxicity inducing signal provided by 
the binding of antigen to its receptor, but that these antibodies 
on the other hand can deliver a signal which triggers cytolysis 
The cytotoxic activity induced by anti-Tl is generally much 
less than the one induced by alloantigen and. therefore, the 
resultant effect of anti-T3 on the cytotoxic activity of Τ cell 
clones is partial inhibition 
The induction of cytotoxicity by anti-T3 reagents resembles 
leclm-dependent cellular cytotoxicity (LDCC) Phytohemag-
glutinin (PHA) and concanavalin A (Con A) induce antigen-
specific CTL clones to mediate nonantigen-specific cytotoxic­
ity [10] This effect of РИА and Con A is not merely a conse­
quence of bridging together target cells and effector cells, 
because wheat germ agglutinin (WGA) which agglutinates 
target cells and effector cells is not able to induce LDCC [31] 
Since PHA and Con A inhibit the binding of anti-T3 reagents 
[32] and WGA docs not (H Spits, unpublished), it is likely 
that PHA and Con A bind to components of T3 Therefore, it 
may well be possible that (part of) LDCC activity is caused by 
triggering of T3 by Con A and PHA The finding reported by 
Wee and Bach [33] that some but not all PTL clones mediate 
I DCC stresses the similarity between anti-T3-dependent 
cytotoxicity and LDCC, since anti-T3 does not induce cytotox­
icity in al) PTL clones (Table 4) 
The demonstration that T3 plays a role m the triggering of 
cytotoxic activity opens a way to study the molecular aspects of 
the mechanism of the "programming for lysis" and "lethal hit" 
stages of the cytotoxic reaction 
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Anti-T3 induced cytotoxicity: the role of target cell Fc-receptors in 
the lysis of autologous monocytes and the Fc-independent lysis of 
T3-positive target cells. 
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Anti-T3 Induced Cytotoxicity: The Role of Target Cell 
Fc-Receptors in the Lysis of Autologous Monocytes and 
the Fc-Independent Lysis of T3-Positive Target Cells 
J.F.M. Leeuwenberg, S.P.M. Lems, and P.J.A. Capel 
WE HAVE SHOWN previously' that anti-T3 monoclonal antibodies 
(MAb), in addition to blocking specific CTL 
target-cell interaction, are able to induce lysis 
of nonspecific targets. By using F(ab')2 frag­
ments of anti-T3 MAb, induction of lysis was 
shown to be Fc-depcndent'·2; and in the analy­
sis of a panel of different target cell types, only 
those targets with demonstrable Fc-receptors 
(FcR) for murine IgG (sub)classes, were 
lysed by cytotoxic Τ lymphocytes (CTL) in 
the presence of anti-T3 MAb of the appropri­
ate subclass.2 Anti-CD8, anti-CD4, anti-CD7, 
and anti-HLA are ineffective in this process, 
indicating thai cell-cell contact via FcR bridg­
ing of antibody coated CTLs and targets is not 
sufficient to induce nonspecific lysis. Activa­
tion of the lytic machinery of the CTL via T3 
crosslinking by FcR on the target cells, there­
fore, is a prerequisite for this process. 
As an approach to the understanding of the 
effects of anti-T3 MAb in vivo, we show here 
that in addition to the lysis of FcR-positive 
cell lines and heterologous monocytes, CTLs 
are also able to kill autologous monocytes, ie, 
monocytes from the same individual from 
whom the CTLs were derived. Furthermore, 
evidence is produced for an Fc-mdependent 
anti-T3-induced lysis. The latter phenomenon 
was dependent on the use of T3-positive tar­
gets, and this suggests a CTL target-cell 
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lands 
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bridging via the binding of the F(ab')2 parts 
of the divalent IgG molecule to the T3 anti­
gens on CTL and target. 
MATERIALS AND METHODS 
MAb used were WT3I (anli-T cell receptor),3 WT32 
(anti-CDa)," WT82 (anti-CD8),' WT1 (anli-CD?),5 and 
7-24 (anti-HLA class I common). F(ab')2 fragments of 
WT32 were prepared as described ' An IgG2b switch 
variant of WT31 (IgGI) was obtained by seeding 100 
hybridoma cells of WT31 per microwell using a total of 
ten plates. After six days, culture supernatants were 
screened for IgG2b antigen activity by an enzyme-linked 
immunosorbent assay (ELISA), using coated Goal anli-
Mouse Ig (Cappel) and Goal anti-Mouse lgG2b peroxi­
dase (Nordic Pharmaceuticals, Quebec) Positive wells 
were cloned twice and analyzed for anti-T3 activity. 
Cell lines used were the В cell lines' SB, Daudi, and 
Raji; the Τ cell lines- СЕМ, Jurkat, and HPB-all, the 
erythromyeloid cell line K562; and Ihe monocytic cell 
lines U937 and HL60 Monocytes were obtained by 
elutnation of peripheral blood mononuclear cells.' Mono­
cytes from an individual whose Τ lymphocytes respond to 
anti-T3 MAb of the IgGl subclass in mitogenesis are 
indicated as responder (mono R); monocytes unable to 
support mitogenesis by IgGl anti-T3 are indicated as 
nonresponder (mono NR) " 
CTLs, specific for the cell line SB, were prepared and 
assayed as described previously ' FcR expression on tar­
get cells was determined in immunofluorescence using 
heal-aggregated mouse IgG subclasses as described ' 2 
RESULTS 
MAb anti-T3 inhibit the specific lysis of 
CTLs but are also able to induce the lysis of 
nonspecific targets. As described previously,1 
FcR+ target cells are susceptible to this phe­
nomenon. In an analysis of the susceptibility 
to anti-T3-induced lysis of a panel of different 
target cell types, CTLs were tested for their 
ability to lyse the FcR" Τ cell lines CF.M, 
Jurkat, and HPB-all. It was observed that the 
T3 + lines Jurkat and HPB-all were lysed, 
whereas the T3~ cell line СЕМ was not (data 
not shown). Optimal lysis of Jurkat and HPB-
Transplantation Proceedings. Vol XIX, No 1 (Februaryl, 1987 pp 4 2 8 - 4 3 1 
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all was induced by anti-T3 MAb of either the 
IgGl, IgG2a, or IgG2b subclass at a concen­
tration of 500 ng/ml, whereas MAb anti-
CD8, CD7, or HLA were ineffective Because 
Jurkat and HPB-all have no delectable FcR 
for mouse IgG, these results suggested an 
Fc-mdependent, T3-dependent mechanism of 
anti-T3-induced lysis, which was investigated 
further by using F(ab')2 fragments of anti-T3 
MAb WT32 and inhibition studies with 
human serum 
As shown in Fig 1, F(ab')2 fragments of 
WT32 were inefFective in the induction of 
lysis of T3 target cells, regardless of their 
FcR expression By contrast, the T 3 + target 
cells Jurkat and HPB-all were shown to be 
lysed effectively In a second set of experi­
ments it was investigated whether the lysis of 
T3 + target cells by intact WT32 could be 
inhibited by Human Serum (HS) as a source 
of human IgG As is shown in Fig 2, lysis of 
FcR*, T3~ targets was blocked efficiently by 
10% US, as also observed previously,2 whereas 
the lysis of Jurkat and HPB-all either was not 
or was only slightly affected 
These results show that the T3 + cells are 
lysed in an Fc-mdependent way We conclude, 
% inhibition 
100 τ 
target 
FcR l g G 2 e 
T 3 
Fig 1 Induction of nonspecific cytotoxicity by 
Flab 12 fragments (500 ng/ml) of W T 3 2 (anti-T3 lgG2a) 
in relation to the expression of FcR for mouse lgG2a or 
T3 on the various target cells by CTLs specific for the 
cell line SB at an effector target ratio of Э0/1 
FcB lgG2a • • • • » • * - -
T 3 
Fig 2 Inhibition of nonspecific cytotoxicity induced 
by 30 ng/ml W T 3 2 (вті-ТЗ lgG2a) by 1 0 % heat-
•nactivated human serum, in relation to the expression 
of FcR for mouse lgG2B or ТЭ on the various target cells 
by CTL specific for the cell line SB at an effector target 
ratio of 3 0 / 1 
therefore, that an effective bridging of CTL 
and target can also occur via the T3 complex 
on CTL and target Consequently, it may be 
expected that CTLs will lyse themselves in the 
presence of anti-T3 Indeed, this kind of CTL 
cannibalism was recently reported by Schrez-
enmeier et al' using a CTL clone However, 
when we incubated 51Cr-labeled CTLs with 
anti-T3, we found no evidence for CTL-CTL 
kill, using four different CTL lines with vari­
ous concentrations of anti-T3 (data not 
shown) Therefore, we investigated whether 
our CTL lines were able to kill autologous 
targets per se in an analysis of the susceptibil­
ity to lysis of autologous monocytes, ie, mono­
cytes from the same individuals as the CTLs 
were derived from, as compared to the lysis of 
heterologous monocytes, ie, from a different 
individual 
In Fig 3 results are shown of an experiment 
in which two CTL lines were tested with 
either autologous or heterologous monocytes 
as targets in the presence of anti-T3 of dif­
ferent subclasses and F(ab')2 fragments of 
MAb anii-T3 IgG2a The CTLs, raised 
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against the В cell line SB, originated from an 
individual responding to anti-T3 IgGl in 
mitogenesis (mono R) and from another 
unable to respond to anti-T3 IgGl (mono 
NR). As is shown, no major differences were 
observed in the lysis of the autologous ν the 
heterologous monocyte targets with both CTL 
lines. 
It is also demonstrated that the findings in 
mitogenesis are in concordance with the data 
of anii-T3-induced lysis. Monocytes of a 
responder (R) were killed by anti-T3 IgGl as 
well as IgG2a, whereas monocytes of the 
nonresponder(NR) lacking the FcR for mouse 
IgGl were only killed in the presence of 
anti-T3 IgG2a. As expected, F(ab')2 frag­
ments of WT32 were ineffective. Also, the 
IgG2b switch variant of WT31 was ineffective 
because both donors were shown to be nonre-
sponders to IgG2b anti-T3-induccd mitogene­
sis. 
DISCUSSION 
The anti-T3 dependent induction of non­
specific cytotoxicity requires cell-cell contact 
and a triggering of the lytic machinery of 
CTLs. The importance of cell-cell contact was 
demonstrated earlier by the inhibition of anti-
T3-induced lysis by anti LFA-1 antibodies, 
which prevent cell adhesion.10 That cell-cell 
Fig 3. Induction of nonspecific lysis of 
heterologous or autologous human mono­
cytes by anti-Ti/T3 antibodies oí dif-
ferent subclasses using CTL specific for 
the cell line SB at an effector target ratio 
of 3 0 / 1 . Responder monocytes (non-R) 
express FcR for murine IgGl and lgG2a, 
and nonrasponder monocytes (mono NR) 
only express FcR for murine lgG2a. 
contact alone is not sufficient for the induction 
of lysis is shown by the ineffectiveness of 
antibodies directed to CD8, CD7, or HLA. 
Triggering of the lytic machinery is brought 
about by the crosslinking of either the Τ cell 
receptor or T3, as shown here, or by an 
interaction with the Tl 1 antigen." As is also 
shown, crosslinking may occur via FcRs on 
the target cells, by which this process is Fc-
dependent, or by means of T3 on the target 
cells, by which induced cytotoxicity is Fc-
independenl. This suggests that no additional 
second signals or target cell membrane modi­
fications, which are generated by FcR cross-
linking on target cells, arc required for this 
phenomenon. 
Our results with monocytes show that 
autologous target cells are killed by anti-
T3-induced CTLs. In one of two accom­
panying papers,12 our first clinical results are 
described with anti-T3 MAb WT32. A suc­
cessful reversion of kidney graft rejection was 
demonstrated in most patients. After a period 
of Τ cell elimination, Τ cells reappeared in the 
circulation but without detectable T3. Be­
cause modulation of the ТЗ/Ti receptor com­
plex may lead to ineffective Τ cell function, 
modulation of the T3 antigen was studied as 
the subject of the second accompanying 
report.13 It may be asked whether in addition 
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to Τ cell elimination and modulation of T3 the 
phenomenon of anti-T3-induced lysis, as 
described here, contributes to the effective­
ness of anti-T3 MAb in the treatment of 
rejection crises by the lysis of FcR+ or T3 + 
target cells. 
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SUMMARY 
Addition of monoclonal antibodies (MAb) directed against CD3 or 
against the Τ cell receptor (TCR) to cytotoxic Τ lymphocytes (CTL) can 
resul t in a nonspecific lysis of third party target cells. Two types 
of target cells are susceptible to this type of lysis; Fc receptor 
(FcR) positive cells and CD3 positive cells. FcR positive cells are 
only lysed by anti-CD3 MAb of a given subclass when they express an 
FcR with a react iv i ty for t h a t part icular subclass. This process is Fc 
dependent, because 1) complete concordance was found between FcR 
expression on target cells, as determined by binding of purified 
murine immunoglobulin G (mlgG) subclass aggregates, and the i r 
susceptibi l i ty to lysis by anti-CD3 MAb of the corresponding subclass 
and 2) the lack of react iv i ty of F(ab')2 fragments of anti-CD3, 
provided the target cells did not carry the CD3 antigen. On the other 
hand, when target cells express the CD3 antigen themselves, F(ab')2 
fragments of anti-CD3 also induced lysis. These findings indicate, 
t h a t anti-CD3 MAb can effect crosslinklng of effector and target cells 
via CD3-FcR or CD3-CD3 bridges and combined with act ivat ion of the CTL 
via the CD3 complex, will induce nonspecific lysis. 
On the basis of th i s phenomenon and using CD3 negative target cells, 
the interact ion of human FcR with mlgG subclasses was analysed. 
Different FcR expression p a t t e r n s were observed. K562, Daudi, and Raji 
reacted with mlgGl, mIgG2a and mIgG2b; U937, HL60, and responder 
monocytes (mono R; able to support Τ cell proliferation induced with 
anti-CD3 MAb of IgGl subclass) reacted with mlgGl and mIgG2a; non 
responder monocytes (mono NR) reacted only with mIgG2a. 
The crossreact ìvi ty of the various FcR was determined by inhibition of 
lysis by aggregates of purified mlgG subclasses, or monomeric human 
immunoglobulin G (hlgG) subclasses. The FcR for mlgGl was inhibited by 
aggregated mlgGl. and less efficiently by aggregated mIgG2a, but not 
by monomeric hlgG subclasses. The FcR for mIgG2a on monocytes, and on 
В cells also the FcR for mIgG2b, was inhibited by aggregated mIgG2a, 
hlgGl and hIgG3. Surprisingly, however, the FcR for mIgG2a was blocked 
by aggregated mlgGl on Daudi and Raji cells, but not on monocytes. 
These resu l t s demonstrate t h a t : 1) the functional FcR expression for 
the various mlgG isotypes varies on different cell types; 2) the FcR 
for mIgG2a on monocytes which binds hlgGl and hIgG3 is functionally 
different from the FcR for mIgG2a on В cells, suggesting a 
heterogeneity of th i s receptor. 
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INTRODUCTION 
The CD3/TCR complex on Τ cells plays an important role in Τ cell 
function (1). MAb directed against this complex can have apparently 
opposite effects. Anti-CD3 MAb have inhibitory effects, such as the 
inhibition of specific cytotoxicity or the blocking of the 
proliferation of Τ cells induced by mitogenic stimuli (2, 3). By 
contrast, binding of MAb to the CD3/TCR complex can also result in 
triggering of the Τ cell in an antigen-like fashion, such as the 
induction of mitogenesis (4) and, as we described recently (5,6), the 
induction of nonspecific cytotoxicity. Addition of anti-CD3 MAb to MHC 
restricted CTL resulted in the lysis of third party cells such as the 
cell lines Daudi, Raji, and K562 in an MHC unrestricted way. Besides 
anti-CD3, anti-clonotypic or anti-TCR antibodies can also induce 
nonspecific lysis (7). In a similar way anti-CD3 or anti-clonotype 
producing hybrids become target for CTL by crosslinking CD3 or TCR via 
their own antibodies (8, 9). Heteroaggregates of antibodies and 
anti-CD3 antibodies can induce lysis of cells reacting with the 
antibody, which is conjugated with anti-CD3 (10, 11, 12).It has also 
been established that activation of CTL by means of the CD2 
glycoprotein instead of via the CD3/TCR complex, induces the same 
phenomenon (13). This phenomenon can be used for the analysis of 
various processes, e.g. investigations on the molecular aspects of the 
mechanism of CTL-target cell destruction, the study of network 
relationships between T-cells and anti-idiotypic antibodies, and it 
may eventually be applied for the in vivo treatment of neoplasms by 
using heterodimers of anti-CD3 and anti-target cell antibodies (11). 
In our original report we observed that anti-CD3 induced cytotoxicity 
is an Fc dependent process (5), occurring via the Interaction of the 
Fc-part of anti-CD3 with the FcR on the target cell membrane. Hence, 
we have used this phenomenon as a novel technique in the analysis of 
Fc receptors for mlgG (sub)classes on a number of human cell lines 
amongst which human В cell lines, monocytic cell lines and normal 
human monocytes. The data demonstrate that FcR for mlgG on human 
leukocytes are not only heterogeneous in expression, but also 
heterogeneous in their specificity. It is shown that the expression of 
a particular FcR varied not only from one cell type to another, but 
that the specificity of a given receptor on a certain cell type, e.g. 
the FcR for mIgG2a on В cells, can be functionally different from the 
corresponding FcR for mIgG2a on monocytes. 
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MATERIALS AND METHODS 
Preparation of lymphocytes 
Peripheral blood mononuclear leukocytes (PBL) of normal healthy donors 
were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden) density 
gradient centrifugation (14). 
Antibodies and Ig preparations 
Anti-TCR MAb used was WT31 (mIgGl.15). Anti-CD3 MAb used were 
WT32 (mIgG2a, 16), Leu-4 (mlgGl, Becton Dickinson. Sunneyvale, CA), 
and SPV-ТЗа (mIgG2b, 17). For inhibition and fluorescence studies we 
used MAb PAI, 2-2-1 and 3-1-3-1. PAI (mlgGl) is an anti-idiotyplc 
MAb, raised against the leukocytes from a patient suffering from a 
B-CLL (18). MAb 2-2-1 (mIgG2a), and 3-1-3-1 (mIgG2b) were raised 
against BALB.K spleen cells and reacted with class II and class I H-2k 
antigens respectively (19). These antibodies were Isolated by Protein 
A Sepharose chromatography as described by Ey et al. (20). Sub­
sequently, residual IgG and other Ig contaminations were removed by 
affinity chromatography on Sepharose-4B (Pharmacia, Uppsala, Sweden) 
columns, coupled with (sub)class specific antisera (Meloy Labs, 
Springfield, VA, and Litton Bionetics, Kensington. MD) directed 
against Impurities as described (21). The purified IgG preparations 
were not contaminated (<0.002 mg/ml) by other Ig (sub)classes as 
judged by gel diffusion analysis with isotype-speclfic immune sera. 
Pure human IgG subclass proteins were obtained from the sera of 
patients with multiple myeloma. They were isolated by (NIhhSO« 
precipitation, chromatography on Sephadex DEAE-A50 (Pharmacia) and, 
if necessary, affinity chromatography on Sepharose columns coupled 
with Protein A (Pharmacia) or anti-IgG subclass antisera (CLB 
Amsterdam, The Netherlands). The purity of the Isolated proteins were 
checked by gel precipitation techniques (Mancini, Ouchterlony) and 
haemagglutination inhibition. The percentage of IgG subclass 
contamination was less than 1% (22). F(ab')2 fragments of WT32 
antibodies were prepared as described previously (5). The percentage 
of intact IgG was less than 0.03% as assessed in a radio-immunoassay. 
Cell lines 
The cell lines used in this study were the В cell lines SB, Daudi, 
Raji and RPMI 1788; the Τ cell lines GEM, Jurkat, and HPB-all; the 
null cell line REH; the monocytic cell lines HL60 an U937; and the 
erythromyeloid cell line K562. Monocytes were obtained by elutriation 
of peripheral blood mononuclear cells as described previously (23).In 
previous reports from our laboratory on the mitogenic effect of 
antl-CD3 MAb, a polymorphism was described in the mitogenesis by 
56 
anti-CD3 of the mlgGl (24) and mIgG2b (25) subclass. Individuals, able 
respectively unable to respond to anti-CD3 MAb of the mlgGl subclass 
(70% and 30% of healthy individuals) were indicated as responders (R) 
and non-responders (NR). 
Cloning of Raji cells 
To obtain cells positive and negative in the expresssion of FcR for 
mIgG2a cells, Raji cells were cloned in flatbottom microtiter plates 
(Costar), 1 cell/well, and grown in RPMI 1640, supplemented with 2 mM 
glutamine, 1 mM sodium pyruvate, 50 pg/ml gentamycin, and 10% heat-
inactivated fetal calf serum. After four weeks samples of the growing 
clones were tested in immunofluorescence for the presence or absence 
of FcR for mIgG2a with heat-aggregated (10 min, 630C) mIgG2a, purified 
by protein A Sepharose (Pharmacia, Uppsala, Sweden) chromatography. 
Generation and assay of CTL. 
PBL at lOVml were mixed with 2000 rad-irradiated SB cells (10s 
cells/ml) in serum-free Iscove's medium supplemented with 2 χ ΙΟ- 9 M 
ethanolamin (Merck, Darmstadt, FRG), 35 ]ig transferrin, 5 ug/ml 
insulin, and 2.5 mg/ml bovine serum albumin (BSA; all three from 
Sigma, St.Louis, MO), 1% (v/v) of a dispersion of lipids extracted 
from human plasma (17) and 50 pg gentamycin. After 6 days culturing 
in 24 well plates (Costar) at 370C in the presence of 5% C02 the cells 
were washed and fresh medium was added. After 10 days the cells 
(lO'/ml) were restimulated with the irradiated original stimulator 
cell (lOVml) in the presence of irradiated PBL (lO'/ml) as a feeder 
layer. ' Five days after the second stimulation, the cells were pooled 
and frozen. Ampoules, containing 4 χ IO7 cells were stored in liquid 
nitrogen. 
Cytotoxicity was assessed by the standard s ,Cr release assay. In a 
total volume of 150 μΐ, different concentrations of effector cells 
were incubated in triplicate in the presence or absence of MAb in 
conical-bottom wells (Titertek; Flow Laboratories) before being mixed 
with 51Cr labeled target cells (104 cells per 50 μΐ per well) in RPMI 
1640 supplemented with 0.25% BSA. After a 3-min 50 χ g centrifugation, 
the plates were incubated for 3 hr at 370C followed by centrifugation 
at 550 χ G for 10 min. 100 μΐ of the supernatants were removed from 
each well and counted in a gamma counter. The percentage of specific 
91Cr release was calculated by the following formula: 
experimental release - spontaneous release χ 100 
total release in saponin - spontaneous release 
The results are expressed as the means +. standard deviation of 
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triplicate experiments. 
Inhibition studies 
Inhibition studies with IgG (murine or human) and with human serum (a 
pool from 20 normal donors) were performed by preincubation of 50 μΐ 
of effector cells and 50 μΐ of e iCr target cells with 50 μΐ murine or 
human IgG, during 15 min, before the addition of anti-CD3 MAb. The 
concentration of antl-CD3 MAb used in these inhibition studies were 
chosen such, that the level of Induced lysis in the absence of 
inhibitor was 80 - 100 % of maximal induced lysis. 
Detection of Fc receptors 
Cells (4 χ 10s) were incubated with heat-aggregated (10 min 60*0 
purified mlgG subclasses for 30 min at 40C in a final volume of 100 
μΐ. After washing three times with phosphate-buffered saline 
containing 0.25% BSA and 0.05% NaN3, the cells were incubated for 30 
min at 40C with 50 μΐ of 1/30-diluted fluorescein isothiocyanate 
labeled sheep anti-mouse Ig antibodies (Cappel), preabsorbed with 
Sepharose-coupled human Ig to remove cross-reactive antibodies. 
RESULTS 
Fc-dependency of anti-CD3 induced nonspecific cytotoxicity 
In order to extend our previous observations on the Fc-dependency of 
anti-CD3 induced lysis with amIgG2a MAb (WT32, anti-CD3), we analyzed 
whether the induction with a mlgGl MAb (Leu-4, anti-CD3) was similarly 
Fc-dependent. CTL specific for the cell line SB were preincubated with 
various concentrations of Leu-4, WT32 , or their F(ab')2 fragments 
before adding 51Cr labeled Daudl cells as targets. As shown in Fig.l, 
intact mlgGl MAb (Panel A) as well as intact mIgG2a MAb (Panel B) 
induced lysis in a dose dependent way, whereas their F(ab,)2 fragments 
did not. 
To investigate whether target cell Fc-receptors were involved in this 
process, a panel of different target cells was tested for the presence 
of Fc receptors in relation to their susceptibility to nonspecific 
lysis. Susceptibility to lysis was determined using dilution series of 
anti-CD3 MAb. Fig. 1 may be taken as an example of such an analysis, 
and the overall results are listed in Table I. 
FcR expression for the different subclasses of mlgG was determined on 
the target cells by immunofluorescence (IF) using heat-aggregated 
purified mlgG subclasses. The results as shown in Table I demonstrate 
that target cells without detectable FcR expression were not lysed by 
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Table I. 
Comparison of anti-CD3 induced lysis with FcR specificity. 
target 
cell 
monocytic cells: 
U937 
HL60 
mono R 
mono NR 
В cell lines: 
Daudic 
Rajic 
RPHI 1788 
SB 
erythromyeloid 
cell line: 
K562c 
Τ cell line: 
СЕИ 
null cell line: 
REH 
================== 
mlgGl 
lysis8 
++ 
+ 
++ 
-
++ 
+ 
-
-
+++ 
-
-
FcRb 
+ 
+ 
+ 
-
+ 
+ 
-
-
+ 
-
-
mIgG2a 
SS——sssss 
lysis 
+++ 
+++ 
+++ 
+++ 
+ 
+ 
-
-
++ 
-
=========== 
FcR 
+ 
+ 
+ 
+ 
+ 
+ 
-
-
+ 
-
-
mIgG2b 
lysis FcR 
-
-
-
-
+ + 
+ + 
-
-
++ + 
-
-
• Nonspecific lysis by CTL in the presence of WT31 (anti-TCR, 
mlgGl, WT32 anti-CDS, т ^ с г а ) , and SPV-ТЗа (anti-CD3, т^СгЬ), 
reaching plateau value In a range of 200-500 ng anti-CD3 MAb/ml 
(+); 50-200 ng/ml (++); 10-50 ng/ml (+++). 
b
 Immunofluorescence with mlgG aggregates of different subclasses 
to detect mFcR; positive signal at a concentration of 50 pg/ml 
aggregate: (+). 
c
 No cytolysls of Daudl. Raji. and K562 was observed in the 
absence of MAb. 
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% ^ С г release 
1.6 40 1000 1.6 40 1000 
ng ant¡-CD3/ml 
Fig.l. Induction of nonspecific lysis of Daudi cells by anti-CD3 MAb 
of the mlgGl (Panel A) and the mIgG2a (Panel B) subclass, either 
mtact (closed symbols) or their F(ab')2 fragments (open symbols). The 
target to effector ratio was 1 10. 
CTL in the presence of anti-CD3 MAb, and that only those target cells 
which were positive for a particular subclass in the fluorescence 
assay, were lysed by anti-CD3 MAb of that particular subclass. In 
addition, the results obtained with monocytes agreed completely with 
the findings of previous mitogenesls experiments. Responder-type 
monocytes (mono R) reacted with mlgGl aggregates in IF, and were lysed 
by mlgGl anti-CD3 MAb, whereas non-responder monocytes (mono NR) 
were not lysed by mlgGl anti-CD3. Similarly, the monocytes from both 
types of donors were of non-responder type for the mitogenic effect of 
mIgG2b anti-CD3 MAb (data not shown), and were also not lysed by CTL 
in the presence of this MAb. 
In order to further study the close relationship between the FcR 
expression on the target cells and their susceptibility to lysis, we 
subcloned the cell line Raji and selected cells with or without FcR 
for mIgG2a. Subsequently, these two sub-lines were tested with a 
mIgG2a MAb anti-CD3, and the results in Fig. 2 show, that only the 
Raji cells expressing FcR for mIgG2a, were lysed. 
Fc independent lysis of CD3 positive target cells 
Although the above presented data clearly show an Fc dependency of the 
anti-CD3 induced lysis, also an Fc independent pathway exists. When 
various target cells, monocytes responder and nonresponder, U937, 
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% 5 1Сг release 
з о . 
20 . 
10 
0.01 0 1 1 10 
μ9 WT32/ml 
Fig 2 Lysis ol cloned Raji cells, either aggregated inlgG2a positive 
( · - · ) or negative (•-») in immunofluorescence, Ly nonspecific CTL in 
the presence or absence of WT32 (anti-CD3 MAb. mlgG2a) The shaded bar 
represents the percent of lysis of Raji Lcllb uilhout addition иГ 
antibody The target to effector ratio was 1 10 
5 1 
,—% Cr release-
60 
4 0 
20 
10 30 
EFFECTOR / TARGET RATIO 
Fig J Induction of lysis of CDJ-positue cells (Jurkat Ш-Ш, HPE-dli 
· - · ) and tDJ-negative cells (K562 and ('EMO-O. Daudi and bíijiD-ü, 
monocytes Я, U937, and HLt)üo-o) by ['(ab )2 fiagiuunls of ttT32 
(arili-CD3, mlgli2a) at a final concentrai ion of -10 ng ml 
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HL60, Daudi, Raji, K562. СЕМ. Jurkat, and HPB-all were incubated with 
40 ng/ml F(ab')2 fragments of WT32 and subsequently tested for lysis 
using SB-specific CTL, only the CD3 positive target cells Jurkat and 
HPB-all were lysed as is shown in Fig. 3. 
Inhibition of anti-CD3 induced lysis by murine IgG aggregates 
Having demonstrated the heterogeneous expression of FcR for the 
various mlgG subclasses on various CD3 negative cell types (Table I), 
we investigated the specificity of different FcR using the inhibition 
of anti-CD3 Induced lysis by mlgG subclass aggregates. CTL and target 
cells were mixed and preincubated with aggregates of different 
subclasses of mlgG at various concentrations, before adding anti-CD3 
MAb. In Fig. 4 a representative experiment out of a sery of four 
experiments is shown of the induction of lysis by anti-CD3 mlgGl of 
Daudi cells and of human responder-type monocytes as targets. The FcR 
for mlgGl was blocked by mlgGl aggregates on both cell types. This 
receptor, however, was also blocked, although somewhat less efficient, 
by mIgG2a aggregates. 
A different pattern was observed with the FcR for mIgG2a. On all cell 
types this receptor was blocked by mIgG2a aggregates. This receptor, 
however, was also blocked by mlgGl aggregates on Daudi cells, but not 
on monocytes (Fig. 5). Lysis of HL60 an U937 by mIgG2a anti-CD3 MAb 
was also not inhibited by mlgGl aggregates (data not shown). When 
monomeric mIgG2a was used as blocking agent, the FcR for mIgG2a was 
blocked on monocytes, but not on Daudi cells (data not shown). These 
results indicate that the FcR for mIgG2a on monocytes and monocytic 
cell lines differs functionally from the mIgG2a FcR on Daudi cells. 
The FcR for mIgG2b was Investigated on Daudi cells. Aggregates of 
mlgGl and mIgG2a blocked this receptor on Daudi cells, indicating an 
extensive cross-reactivity of this FcR (data not shown). 
Inhibition by human myeloma IgG 
In an attempt to delineate the natural ligands of FcR for mlgG, 
inhibition studies were performed with human myeloma IgG. Monomeric 
hlgGl, hIgG2, hIgG3, and hIgG4 were tested in different concentrations 
with human monocytes and Daudi cells as targets. As is shown in Table 
II, the FcR for mIgG2a was inhibited by hlgGl and hIgG3 on both 
monocytes and Daudi cells, whereas the FcR for mIgG2b on Daudi cells 
behaved essentially the same. The FcR for mIgG2b was absent on the 
monocytes tested. However, none of the human myeloma's was able to 
block the FcR for mlgGl on Daudi cells, and only a slight inhibition 
was observed on monocytes. The overall results of the inhibition 
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% inhibi t ion 
monocytes 
0.3 1.7 10 62 0.3 1.7 10 62 
\ig aggregate/ml 
Fig 4 Inhibition of WT31 (anti-TCR, mlgGl) induced 1>¡>1¡> by murine 
aggregates of the IgGl (Α-A) subclass, and of llic lgG2d ( · - · ) 
subclass The target to effector rallo mas 1 10 
% inhibi t ion 
100 
0.3 1.7 10 0.3 1.7 10 62 
pg aggregate/ml 
Fig 5 Inhibition of \ ТУ2 (anti-CD3, mIgGÜa) induced Ijsis b> murine 
aggregates of the IgGl (Α-A) subclass and ol the IgCCa ( · - · ) 
subclass The target to effector ratio was 1 IÜ 
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Table II. 
Effect of human myeloma IgG on the lys is of Daudi cells and 
monocytes induced by MAb anti-CD3 of different subclasses. 
% i n h i b i t i o n of l y s i s 8 
human Daudi monocytes 
myeloma =========================== ================ 
(mg/ml)b mIgGlc mIgG2ad mIgG2be IgGl c mIgG2ad 
IgGl 1.250 0 90 70 10 85 
0.250 0 80 60 5 75 
0.050 0 40 40 0 55 
IgG2 0.625 0 5 0 15 20 
0.125 0 0 0 0 5 
0.025 0 0 0 0 0 
IgG3 1.250 15 80 80 35 100 
0.250 5 25 40 15 95 
0.050 0 10 20 5 75 
IgG4 0.125 0 0 0 5 20 
0.025 0 0 0 10 10 
0.005 0 0 0 0 0 
B
 The target to effector ratio was 1:30 
ь
 Final concentration 
c
 WT31 (anti-TCR MAb mlgGl) was added at a final concentration 
of 26 pg/ml to Daudi cells and of 250 pg/ml to monocytes. 
d
 WT32 (antl-CD3 MAb mIgG2a) was added at a final concen­
tration of 50 pg/ml to Daudi cells and to monocytes (R). 
e
 SPV-ТЗа (anti-CD3 MAb mIgG2b) was added at a final concen­
tration of 250 ug/ml to Daudi cells. 
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experiments with the B-cell line Daudi and monocytes as ta rge t s are 
summarized in Table III. 
Table III. 
Inhibition of anti-CD3 Induced lysis by aggregated and monomeric 
murine IgG, and monomeric human IgG. 
i n h i b i t o r 
t arget ============================================= 
aggregated monomeric monomeric 
c e l l =========== ======== ========================== 
FcR mlgGl mIgG2a mIgG2a hlgGl hIgG2 hIgG3 hIgG4 
mono Ra mlgGl + b + -
mIgG2a + + + + -
Daudi mlgGl 
mIgG2a 
mIgG2b 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
8
 Similar resu l t s were obtained using HL60 and U937. 
ь
 At a concentrat ion of 50 pg/ml aggregated mlgG, 
monomeric mlgG, and 500 ug/ml monomeric hlgG more 
inhibition (+). 
100 yg/ml 
than 40% 
DISCUSSION 
The Fc dependent anti-CD3 induced cytotoxicity is used to analyze the 
FcR on monocytes and В cell l ines. Addition of anti-CD3 or anti-TCR 
MAb to CTL resu l t s in the lysis of t h i r d - p a r t y cells such as Daudi, 
Raji and monocytes. We could demonstrate t h a t th i s phenomenon is an Fc 
dependent process: firstly, highly purified F(ab')2 fragments of 
anti-CD3 were not able to induce lysis; secondly, complete concordance 
was observed, when the susceptibi l i ty to anti-CD3 induced lysis of a 
panel of different cell types was compared with the react iv i ty with 
mlgG aggregates in immunofluorescence; thirdly, a subclone of Rajl 
cells, lacking the FcR for mIgG2a was not lysed by anti-CD3-IgG2a. The 
proposed mechanism is, t h a t the F c - p a r t of the ant i-CD3, bound to the 
CD3-complex on the effector cells, binds to the FcR on the target 
cell. In th i s way a bridge between the ta rge t and the CTL is formed, 
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resulting in an effective triggering of the lytic machinery of the CTL 
by crosslinking the CD3-complex. 
With the presence of CD3 as well on the target as on the effector 
cells, a similar type of bridging can occur via the CD3 antigen on the 
target and effector cell, resulting in an Fc-independent lysis. This 
mechanism was observed with F(ab')2 fragments of anti-CD3 on CD3 
positive target cells. 
Although Schrezenmeier et al. (26) failed to show FcR dependent 
killing of nonspecific target cells by cytotoxic Τ cell clones in the 
presence of anti-CD3 MAb, Staerz et al (27) confirmed the Fc 
dependency in the mouse system with a MAb of mIgG2a subclass directed 
against the Τ cell receptor; only those targets, which expressed 
receptors for mIgG2a were lysed by CTL, incubated with the MAb. 
Similarly Gullberg et al. (28) demonstrated, also in a mouse system, 
nonspecific killing of В cells by CTL in the presence of a 
rabbit-anti-mouse brain antiserum, which could activate Τ cells. This 
lysis was inhibited by normal rabbit IgG, which also indicates Fc 
involvement. 
Having established the Fc-dependency of the induction of nonspecific 
cytotoxicity for CD3 negative target cells, this phenomenon was used 
as an assay for FcR characterization. The presence or absence of FcR 
for the different subclasses of mlgG was demonstrated by using 
anti-CD3 or anti-TCR MAb of different subclasses. With this approach 
it 'was shown that Daudi, Raji and K562 cells were positive for mlgGl, 
mIgG2a, and mIgG2b; monocytes and the monocyte related cell lines U937 
and HL60 were positive for mlgGl and mIgG2a and monocytes 
non-responsive in the mIgGl-anti-CD3 induced mitogenesis were only 
positive for mIgG2a. 
Our data show, that at least functionally the mlgGl, mIgG2a, and 
mIgG2b subclasses are handled differently by the various cell types, 
and that for a given FcR the crossreaction patterns with other 
subclasses can vary also for the different cell types. 
Experiments of anti-CD3 induced proliferation of Τ cells show a 
monocyte dependent polymorphism in the handling of mlgGl and mIgG2b 
antibodies. This could be ascribed to the presence or absence of 
functional FcR for these subclasses (24, 25). Monocytes from 70% of 
the Caucasian population display a receptor for mlgGl and less than 
10% a receptor for mIgG2b (25). Not only mlgGl-/mIgG2a+/mIgG2b-
indlviduals are described, but also mlgGl-/mIgG2a+/mIgG2b+ individuals 
(25). This indicates the existence of three functionally distinct FcR. 
However, from these data one cannot conclude that these functions are 
also located in three separate receptor structures. Although three 
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biochemically different FcR have been described (29) localisation of 
a function to only one receptor is difficult, due to the 
crossreactivity of these receptors with other subclasses. Minor 
variations either in the receptor itself or in the quantitative 
expression can influence the outcome of a test. The definition of the 
presence or absence of a receptor will depend on the sensitivity of 
the assay used. An example of different results obtained with 
different tests is the polymorphism of the mlgGl FcR on human 
monocytes. This polymorphism is clear-cut and genetically determined 
(25) when measured in anti-CD3 induced proliferation. However, using a 
very sensitive quantitative rosette assay, this receptor could still 
be detected on monocytes lacking accessory function in anti-CD3 
induced Τ cell proliferation. This expression, at least functionally, 
was much less in these individuals (30). 
Besides quantitative differences minor variations within the receptor 
might be responsible for the functional differences as was shown by 
Anderson et al. (31), who observed differences in isoelectric 
focussing patterns of purified FcR for mlgGl between high and low 
responder monocytes. Our data show that В cell lines display a 
different crossreactivity pattern in comparison with monocytes for the 
mIgG2a FcR, when tested with mlgGl aggregates. From this difference, 
however, one cannot postulate entirely different receptor types, but 
qualitative or quantitative differences might explain these results. 
The crossreaction patterns which can vary per cell type makes that the 
choice of cells together with the sensitivity of the assay used, are 
important for the observed specificity of the receptors studied. In 
this respect the literature is conflicting concerning the presence of 
mIgG2a FcR on the cell lines Daudi, Raji, and K562. Our data show a 
functional mIgG2a FcR on these cells, and it has also been reported 
that mIgG2a inhibit EA rosette formation on K562 cells (32). On the 
other hand, measuring the function of K562 to induce interleukin-2 
release from Jurkat cells in the presence of antl-CD3 MAb, Leu 4 
(mlgGl) was active and OKT3 (mIgG2a) was not, suggesting the absence 
of a mIgG2a FcR (33), and the same was found for Daudi cells (34). Our 
explanation for these different findings is that these might be due to 
differences in sensitivity of the assay used. Furthermore, FcR 
expression on cell lines can vary in time and are dependent on cell 
cycle (35, 36). We were able to clone Raji cells at the single cell 
level, and obtained FcR-mIgG2a positive and negative clones. Long 
term culture of more than four weeks of these clones resulted in the 
gradual reappearance of the FcR for mIgG2a on the initially FcR-mIgG2a 
negative clones. 
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Our data show, that the receptor for mlgGl does not react with 
monomeric human IgG, and that this receptor, when present on human 
cells, crossreacts with mIgG2a. This receptor has recently been 
characterized as the 40 kD FcR by Anderson et al. (31). The FcR for 
migG2a is present on human monocytes, the cell lines U937 and HL60, 
and is the high affinity 72 kD FcR (34). This receptor Is also present 
on K562, Daudi, and Raji. On Daudi cells this receptor crossreacted 
with mlgGl in contrast to the FcR on monocytes, HL60 and U937 which 
did not show any reactivity with mlgGl, Indicating functional 
differences of this receptor on various cell types, which suggests 
heterogeneity of this receptor. This FcR for mIgG2a reacted in all 
cases with monomeric human IgGl and IgG3. 
The FcR for mIgG2b was only detectable on K562, Daudi and Raji and not 
on other cell types tested. When present, this receptor had a 
comparable inhibition profile with other subclasses as the FcR for 
mIgG2a on these cells. The different cellular expression in comparison 
with the FcR for mIgG2a could suggest a distinct receptor for mIgG2b. 
On the other hand the inhibition profile was similar to the FcR for 
mIgG2a. Our preliminary data obtained from comodulation studies, 
suggest that mIgG2b can be bound to the FcR for mlgGl. Therefore. 
further studies are necessary before it can be concluded whether the 
FcR for mIgG2b Is a separate receptor, or the observed reactivity is 
due to a crossreaction of other FcR on these particular cells. 
We can conclude, that the phenomenon of anti-CD3 induced cytotoxicity. 
when using CD3 negative target cells, can be a valuable tool for the 
further analysis of FcR profiles on cells and their specificity. 
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DISCUSSION AND SUMMARY 
This thes i s can be divided in two main subjects. Part one describes a 
s tudy of some MAb against Τ cell differentiation ant igens. The second 
part deals with the interact ion of MAb with human Fc receptors. 
The incent ive of the study of MAb directed against Τ cell 
dif ferentiat ion ant igens was to develop more selective and more 
effective agents for the immunotherapy of renal t ransp lanta t ion 
pat ients , than the conventional polyclonal ATG. An immunosuppressive 
drug can be used e i ther to prevent an immune reaction, or to suppress 
an exist ing immune response. Usually ATG treatment is s ta r ted when the 
rejection has been diagnosed, and th i s will also be the case if MAb is 
used. Prevention, however, of a response may be preferable in some 
par t icu lar cases . 
In Chapter II the character i s t ics of an a n t i - p a n Τ cell MAb (WT1) 
directed against the CD7 antigen, are described. WT1 was prepared by 
the hybridoma technique after immunization of mice with human 
thymocytes. It binds to a 40 kl) glycoprotein (CD7) (1) present on Τ 
lymphocytes, thymocytes, and on most Τ cell l ines. WT1 also reacts 
with the Τ lymphocytes of Rhesus monkeys. This property made WT1 
suitable to s tudy i t s immunosuppressive capacit ies in the Rhesus 
monkey model. Administration of WT1 to Rhesus monkeys carrying skin 
allografts resul ted in prolonged graft survival . The mechanism by 
which WT1 was effective, is not clear. WT1 was administered two days 
prior to t r a n s p l a n t a t i o n , and the animals received daily injections of 
WT1 during the following 10 days. This t rea tment was apparently able 
to delay the induction of an immune response. However, when applied as 
immunosuppressive drug during rejection in a human renal t r a n s ­
plantat ion, successful suppression of the rejection process was not 
obtained. This suggests, t h a t WT1 is not able to influence an ongoing 
immune react ion, but t h a t this MAb might only affect the ini t iat ion 
phase of an immune response. Whether anti-CD7 MAb will be effective in 
clinical t r a n s p l a n t a t i o n , when given prophylactically, is not clear at 
this time. A preliminary report on the prophylactic use of RFT2 MAb 
(anti-CD7) in renal t ransp lanta t ion is not very encouraging; two of 
five p a t i e n t s developed a rejection episode while receiving t reatment 
with RFT2 (2). The binding of MAb directed against CD7 resul ts in a 
rapid modulation of the antigen in vi tro. This process was also 
observed in vivo during administration of WT1 to p a t i e n t s who had a 
rejection of the i r kidney grafts. In these cases, the amount of 
circulating Τ cells in the periphery was not affected by the WT1 
t reatment , but the CD7 antigen was lacking on these cells due to 
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modulation These data suggest, that although the expression of CD7 is 
increased on activated Τ cells, the antigen itself is not involved in 
the actual effector function of the Τ cell Thus, the absence of the 
CD7 antigen from the modulated Τ cells has no influence on their 
function. In vitro, anti-CD7 does not interfere with functional assays 
such as mixed lymphocyte reaction or cytotoxic assays, also indicating 
that the antigen is not directly functionally involved in Τ cell 
activation 
The strong modulation of CD7 after binding of anti-CD7, which might be 
the reason for the in vivo ineffectiveness of WT1 treatment, is on the 
other hand beneficial when this antibody is conjugated with the 
Ricin-A chain This immunotoxin is rapidly internalized by CD7 
positive cells, proved to be very effective in killing of CD7 positive 
leukemic cells, and can be used for purging of bone marrow from 
patients suffering from acute lymphatic Τ cell leukemia, prior to 
autologous bone marrow grafting (3) 
In contrast to WT1, MAb directed against the CD3 complex interfere in 
different functional assays, presumably because CD3 Is closely 
associated with the Τ cell receptor. Foreign antigens initiate an 
immune response via binding of the Τ cell receptor resulting in 
activation of Τ cells. Antl-CD3 MAb inhibit this activation process, 
when specific antigen is used as stimulator, the antigen specific 
cell-mediated lympholysis and the proliferation to soluble antigen are 
blocked by anti-CD3 MAb (4, 5) On the other hand, anti-CD3 MAb can 
also mimic antigen by binding to the CD3/T cell receptor complex, and 
in this way activating Τ cells in an antigen nonspecific way, such as 
induction of mitogenesis, release of interferon-gamma, expression of 
1L¿ receptors (6, 7, 8, 9). Furthermore, as described in Chapter III, 
anti-CD3 MAb induce nonspecific killing of third-party cells by 
cytotoxic Τ cells (CTL) 
Cell-mediated lympholysis can be divided into several steps (10). 
Initially, adhesion of CTL to the target cell occurs This phase is 
antigen-independent and can be blocked, accordingly to the Τ cell 
phenotype, by anti-CDS, anti-CD4, ann-CO2, and anti-LFA-1 MAb 
The adhesion step is followed by the "programming for lysis", after 
which the lethal hit" will be delivered This process can be 
inhibited by anti-CD3 MAb. However, as described in Chapter III and 
the following Chapters, anti-CD3 MAb can also trigger antigen-specific 
cytotoxic Τ cells to lyse antigen nonspecific target cells This 
phenomenon is called anti-CD3 induced cytotoxicity", and was only 
observed with activated Τ cells, obtained from a mixed lymphocyte 
culture (MLC) or with Τ cell clones Whereas cytotoxic Τ cells show 
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nonspecific cytotoxicity, freshly isolated peripheral blood 
lymphocytes and thymocytes did not show nonspecific cytotoxicity in 
the presence of anti-CD3 MAb. The lytic capacity is apparently not 
functionally present in these resting cells, but becomes operational 
once the "future cytotoxic" Τ cells are activated by antigen, mitogens 
or anti-CD3 antibodies. 
When a panel of different Τ cell clones was investigated lor their 
capacity to lyse nonspecific target cells in the presence of anti-CD3 
MAb, CD4 positive as well as CD8 positive Τ cell clones could be 
induced to nonspecific cytotoxicity by anti-CD3 MAb. Not only antigen 
specific cytotoxic Τ cell clones, but also noncytotoxic antigen 
specific proliferating Τ cell clones were rendered susceptible to 
nonspecific lytic activity by anti-CD3 MAb. However, two antigen 
specific proliferating Τ cell clones were found, which could not be 
induced to nonspecific lytic activity, indicating that not all 
activated Τ cells per se possess a lytic machinery (Chapter IV) 
Induction of nonspecific lysis requires more than only divalent 
binding of antibody to the CD3 complex, F U b ' ^ fragments of anti-CD3 
were unable to induce lysis of CD3 negative target cells, whereas 
intact antibodies did, provided the target cells expressed an FcR for 
the appropriate murine IgG subclass used in the system When the 
target cells expressed the CD3 antigen, F(ab')2 fragments of anti-CD3 
were also able to induce lysis of these cells (Chapter V and VI). 
These findings may explain the mechanism by which anti-CD3 induced 
lysis is effective, anti-CD3 forms a bridge between the target cell 
and the CTL via either the FcR or the CD3 complex on the target cell 
and the CD3 complex on the CTL. This bridge formation leads also to 
crosshnking of the CD3 complex on the CTL, resulting in triggering of 
the lytic machinery, and subsequently in lysis of the target cell. In 
this proposed mechanism the CD3 complex plays a pivotal role in signal 
transduction leading to the activation of the lytic machinery A 
similar result can be obtained when a combination of anti-CD2 MAb are 
used, nonspecific lysis can occur in the presence of anti-Tll2 and 
anti-ТІІэ MAb (11) This is the same combination which can activate Τ 
cells, resulting in proliferation and IL2 release (12). When MAb 
directed against other diflerentiation antigens were tested, none of 
them were able to induce cytolytic activity, indicating that only 
antigens involved in Τ cell activation deliver the appropriate signal 
by which the lytic machinery is triggered. 
Since FcR expressing cells or CD3 positive cells can be lysed 
nonspecifically in the presence of anti-CD3 MAb, autolysis of CTL 
could theoretically also occur In our experiments, however, autolysis 
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of CTL was not observed It has been described, t h a t CTL per se can 
be lysed by other CTL, when CTLA directed against B, and CTLB directed 
against C, were mixed, unidirectional killing of CTLB occurred (13) 
Kranz and Eisen (14) compared the susceptibi l i ty to lysis of CTL and 
noncytolytic cell l ines by e i ther a CTL clone or CTL, derived from an 
MLC Their resu l t s indicated t h a t CTL a ie more r e s i s t a n t to lysis t h a n 
the other oell types tes ted. The susceptibi l i ty to lysis appeared to 
be dependent on the aggressor CTL, the CTL-targets were completely 
r e s i s t a n t to lysis by some, but not all the CTL, tested as effector. 
These findings may explain resul ts of other invest igators , who 
described autolys is of CTL in the presence of anti-CD3 MAb (15) 
Autologous monocytes, however, are not spared from lysis by 
autologous CTL in the presence of anti-CD3 MAb (Chapter V) The 
importance of th i s phenomenon in the in vivo t reatment of anti-CD3 MAb 
as immunosuppressive drug during rejection of allografts has ye t to 
be elucidated. Many cells, including CTL are thought to play a role in 
the rejection of allografts, e.g. act ivated macrophages, В cells, and 
antibody dependent cellular cytotoxic (ADCC) cells These cell types 
are all gathered in the battlefield of rejection and express FcR. It 
is possible t h a t not only CD3 positive cells but also FcR positive 
cells are killed by CTL during t r e a t m e n t with ant i-CD3, result ing in 
removal of various types of immunoreactive cells, which are 
responsible for the rejection. 
The anti-CD3 induced cytotoxicity can be used to study different 
processes such as the molecular aspects ol the mechanism of CTL-target 
cell destruct ion, or the analysis ol network re lat ionships between Τ 
cells and anticlonotypic antibodies A clinical application may be the 
in vivo t r e a t m e n t of tumors, using heteroaggregates of anti-CD3 and 
ant i - tumor specific antibodies (16) Similarly, heteroconjugates of 
anti-TCR MAb and MAb specific for inluenza A virus proteins may be an 
approach in a n t i - v i r a l therapy (17). Since FcR positive target cells 
are susceptible to the anti-CD3 induced lysis, th i s phenomenon 
provides a useful approach for the s tudy and the analysis of FcR 
The second par t of this thesis dealb with the character izat ion of FcR 
for murine IgG on human leukocytes (Chapter VI). The anti-CD3 induced 
lysis occurs via the interact ion of the F c - p a r t of anti-CD3 with the 
FcH on the ta rge t membrane, provided these ta rge t cells are CD3 
negative. The presence or absence of FcR for a par t icular (murine) IgG 
subclass could be invest igated using anti-CD3 MAb of different IgG 
subclasses The FcR expression was studied on human cell l ines 
amongst which human В cell l ines, a proerythromyeloid cell line 
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(КобЗ), monocytic cell l ines (HL60 and U937), and normal human 
monocytes. Different FcR expression p a t t e r n s were observed, some cell 
types were react ive with murine IgGl, IgG2a, and IgG2b (B cell l ines, 
K562), others with murine IgGl and IgG2a (HL60, U937, monocytes). 
whereas also cells only react ive with murine IgG2a were found 
(monocytes from circa 30% of the individuals) . The specificity of FcR 
was analyzed by inhibition s tudies of the FcR with aggregates of 
punl ied murine IgG subclasses, and monomeric human IgG subclasses on 
human monocytes and the В cell line Daudi. The FcR for murine IgGl can 
be blocked by murine IgG2a, but not by human IgG subclasses. The FcR 
lor murine IgG2a, however, can be blocked by human IgGl and IgG3. 
Aggregates of murine IgGl are able to block the receptor for murine 
IgG2a on Daudi cells, but not the receptor for murine Ig2a on 
monocytes, suggesting t h a t this receptor is functionally different on 
different cell types. 
In Τ cell proliferation studies using ant i-CD3 MAb it was found t h a t 
30% of the Caucasian individuals did not respond to anti-CD3 MAb of 
the IgGl subclass (18). A polymorphic FcR for murine IgGl on human 
monocytes was responsible for this phenomenon. It was concluded t h a t 
monocytes of some individuals (non responder monocytes) lacked the FcR 
lor murine IgGl. Due to th i s lack of FcR, no crosslinking of the CD3 
complex occurred, which is an essent ia l requirement for Τ cell 
proliferation. Also for the FcR for murine IgG2b a polymorphism was 
observed, mitogenesis could be induced by anti-CD3 of the IgG2b 
subclass in less t h a n 10% of the Caucasian population (19). This 
polymorphism was also observed in the anti-CD3 induced cytotoxicity; 
non responder monocytes were not lysed by CTL in the presence of 
anti-CD3 MAb of the IgGl subclass. A very sens i t ive EA rese t t ing 
assay, however, could st i l l detect an FcR for murine IgGl on the non 
responder monocytes, when very high concentrat ions of sensit izing 
antibody were used (20). Similarly, Clement et al. (21) were able to 
induce mitogenesis in Τ cells of a non-responding individual using a 
thousandfold higher concentrat ion anti-CD3 MAb of the IgGl subclass. 
These findings indicate t h a t the outcome of the t e s t is dependent on 
its sens i t iv i ty, and in the case of mitogenesis, also on the capacity 
ol the FcR positive accessory cell to deliver the second signal, 
necessary ior proliferation of the Τ cells (22). 
Biochemically, three different FcR for human IgG on human cells have 
been described: a 72 kD FcR (FcRI), binding human IgG and murine IgG2a 
and IgG3 is present on human monocytes; a 40 kD FcR (FcRII), is 
expressed on macrophages, p late lets , granulocytes, and В cells and 
binds murine IgGl and very poorly human IgG, and an FcR with very low 
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affinity for human IgG (FcRu) (23), present on neutrophils, 
eosinophils, macrophages, natural killer cells, killer cells, large 
granular lymphocytes, and TY cells. On Daudi cells only the 40 kD FcR 
was isolated (24). Monocytes, on the other hand, express in circa 70% 
of the individuals two different FcR; the 72 Kd FcR and the 40 kD 
receptor. The 40 kD receptor on monocytes has not · the same 
characteristics as the 40 kD receptor on Daudi cells (and on K562 
cells), since it binds no murine Igü2b, and has a lower affinity for 
murine IgGl than the 40 kD receptor on Daudi cells. These results 
indicate, that the FcR are not only heterogeneous in expression, but 
also heterogeneous in their specificity on different cell types. 
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SAMENVATTING 
In dit proefschrift is onderzoek beschreven naar de biologische 
werking van monoclonale antistoffen (MAb) gericht tegen bepaalde Τ cel 
differentiatie antigenen. Dit onderzoek is gedaan in het kader van de 
klinische toepassing van MAb als immunosuppressivum. Het immuun­
systeem is verantwoordelijk voor een rejectie van een t r a n s p l a n t a a t , 
en Τ cellen spelen hierin een belangrijke rol. Behandeling van 
pat iënten met polyclonaal an t i - thymocyten globuline (ATG) met als doel 
de Τ cellen u i t te schakelen, heeft reeds tot succes geleid. Echter 
gebruik van MAb tegen gedefinieerde Τ cel differentiatie ant igenen 
maakt een specifieke react ie mogelijk, met minder nadelige 
bijwerkingen. 
In de Inleiding (Hoofdstuk I) is een overzicht gegeven van to t nu toe 
beschreven a n t i - T cel MAb. 
In Hoofdstuk II is een a n t i - p a n Τ cell MAb (WT1) gericht tegen het CD7 
antigeen gekarakter iseerd. Gebruik makend van de eigenschap dat WT1 
ook met de Τ lymfocyten van de Rhesus aap reageert , is onderzoek 
gedaan naar de immuunsupprimerende werking van WT1 in het 
h u i d t r a n s p l a n t a t i e model van de Rhesus aap. Toediening van WT1 
resul teerde in een significante verlenging van het a l l o t r a n s p l a n t a a t . 
Nadien is WT1 toegediend tijdens rejecties van humane 
n i e r t r a n s p l a n t a t e n , echter zonder succes. 
Naast de klinische toepassing zijn a n t i - T cel MAb ook bij u i t s tek 
geschikt om het functioneren van Τ cellen te bestuderen. Een 
belangrijk eiwitcompiex op de Τ cel is het CDS complex. Dit complex is 
geassocieerd met de antigeen specifieke Τ cel receptor. Anti-CD3 MAb 
hebben velerlei effecten in functionele assays, zowel remmend als 
act iverend. In Hoofdstuk III is een nieuwe act iv i te i t van anti-CD3 MAb 
beschreven, nl. de anti-CD3 geïnduceerde cytotoxie; ant igeen 
specifieke cytotoxische Τ cellen lyseren in de aanwezigheid van 
anti-CD3 MAb aspecifieke target cellen. Deze aspecifieke lysis is n ie t 
induceerbaar in niet geactiveerde perifere bloedlymfocyten of in 
thymocyten, maar alleen in geactiveerde Τ cellen. 
In Hoofdstuk IV zijn antigeen-specif iek prolifererende Τ cel clonen 
getest . Zowel CD4 als CD8 positieve cytotoxische Τ cel clonen, ais ook 
twee clonen die geen specifieke lyt ische act iv i te i t vertoonden, waren 
induceerbaar tot aspecifieke lyt ische ac t iv i te i t met anti-CD3 MAb. 
Deze gegevens suggereren dat alle geactiveerde Τ cellen over een 
lytisch mechanisme beschikken, ware het niet dat ook twee 
prolifererende Τ cel clonen gevonden zijn, die met anti-CD3 MAb niet 
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geïnduceerd konden worden tot lyt ische ac t iv i te i t . 
Een panel van verschillende cellen is getes t op gevoeligheid voor de 
ant i -CDJ geïnduceerde lysis . Alleen Fc-receptor posit ieve of CD3 
posit ieve ta rge t cellen worden gelyseerd (Hoofdstuk III, V en VI) Het 
veronderstelde mechanisme is, dat ofwel via de Fc-receptoren ofwel via 
het CD3 complex op de target cellen de anti-CD3 MAb het CD3 complex op 
de elfector cel crosslinken, hetgeen een effectieve prikkel 
veioorzaakt in het cytolytisch mechanisme 
Omdat Fc- ieceptoren een grote rol spelen in de immuunrespons en omdat 
de wei king van muis-MAb in in vivo therapie , bijvoorbeeld an t i - tumor 
theiapie of an t i - re jec t i e therapie , waarschijnlijk via Fc-receptoren 
verloopt, is kennis van Fc-receptoren voor muis-lgG op humane cellen 
van groot belang De anti-CD3 geïnduceerde cytotoxie is een gevoelige 
assay gebleken voor de studie van Fc-receptoren op humane cellen. In 
Hoofdstuk VI zijn de functionele eigenschappen van Fc-receptoren op 
humane monocyten en В cellijnen met betrekking to t verschil lende 
Subklassen muis-lgG geanalyseerd Aangetoond is dat op humane 
leukocyten de functionele Fc-receptor voor muis-lgG niet al leen 
heterogeen is voor wat betreft expressie, maar ook voor wat betreft 
specificiteit 
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STELLINGEN 
ι 
BIJ het gebruik van monoclonale antistoffen voor immunosuppressie dient men 
terdege rekening te houden met de vraag of men de inductie fase dan wel de effector 
fase van de immuun respons wil beïnvloeden 
II 
Het vaststellen van een functie voor een differentiatie antigeen leidt vaak ten onrechte 
tot de conclusie dat deze functie de enige is, waardoor het zoeken naar andere 
functies van het betrokken antigeen vertraagd wordt 
III 
Niet alleen het onderscheid tussen 'helper' en 'cytotoxische' Τ cellen op basis van de 
expressie van respectievelijk CD4 en CD8 antigenen is incorrect, maar ook het 
toeschrijven van een enkelvoudige functie aan een Τ cel subset, daar CD4 positieve 
antigeen specifieke Τ helper cellen ook over een cytolytische activiteit kunnen 
beschikken 
IV 
Ondanks de specificiteit van anti-CD3 antistoffen voor Τ cellen die dit antigeen 
dragen, kunnen ook CD3-negatieve cellen target zijn tijdens therapie met anti-CD3 
antistoffen 
V 
Het feit dat CD3-positieve cytotoxische Τ cellen in aanwezigheid van anti-CD3 
antistoffen niet gelyseerd worden hoewel CD3-positieve cellen in principe wel een 
target voor lysis zijn in een dergelijke assay, doet vermoeden dat cytotoxische Τ cellen 
een beschermingsmechanisme tegen auto-agressie bezitten 
VI 
De gevonden specificiteit van een Fc-receptor voor de verschillende Immunoglobuline 
subklassen wordt vooral bepaald door de gevoeligheid van de gebruikte assay 
VII 
Het remmend effect van tumor necrosis factor op de inductie van MHC klasse II 
antigenen door interferon-gamma en het verhogende effect op de expressie van al 
geïnduceerde MHC klasse II antigenen kunnen een rol spelen bij het gelokaliseerd 
houden van de immuun reactie 
VIII 
Ten onrechte veronderstelt Falinski dat in de loop van de vegetatie successie de sex-
ratio van jeneverbes verandert J В falinski Vegetano 43 23-38 (1980) 
IX 
De neiging van politici om 'opdat' te gebruiken in plaats van 'zodat' weerspiegelt hun 
afgenomen vertrouwen in de etfectiuteit van hun eigen maatregelen 
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